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Here we describe chemical innovations that enable the preparation of fully synthetic tetracyclines
containing an all-carbon quaternary, stereogenic center at position C5a, a structurally novel class of
compounds in this important family of therapeutic agents. In the key transformation and an important
extension of the powerful MichaeleClaisen cyclization (AB plus D) approach to the construction of fully
synthetic tetracyclines, we show that the six-membered C ring comprising a C5a quaternary carbon
center can be assembled by highly stereocontrolled coupling reactions of b-substituted AB enones and o-
toluate ester anion D-ring precursors. Novel and versatile b-functionalization reaction sequences em-
ploying tris(methylthio)methyllithium and 2-lithio-1,3-dithiane have been developed to transform the
AB enone 1 (the key precursor to fully synthetic tetracyclines) into a diverse range of b-substituted AB
enone products, including a highly efficient, single-operation method for the synthesis of a b-methyl
ester-substituted AB enone. A C5aeC11a-bridged cyclopropane tetracycline precursor was found to
undergo efficient and regioselective ring-opening reactions with a range of nucleophiles in the presence
of magnesium bromide, thus providing another avenue for the preparation of fully synthetic tetracyclines
containing an all-carbon quaternary center at position C5a. Two compounds prepared from the bridged
cyclopropane intermediate served as (further) diversifiable branch-points, allowing maximally expedient
synthesis of C5a-substituted tetracyclines by final-step diversification.
 2011 Elsevier Ltd. All rights reserved.1. Introduction
To date more than 3000 fully synthetic molecules of the tetra-
cycline class, broadly defined, have been prepared by a general and
convergent process that involves a MichaeleClaisen coupling of the
AB enone 1with structurally diverse D-ring precursors followed by
deprotection, a route of typically 3e4 steps (Fig. 1).1,2 Most of the
candidate antibiotics prepared in this way would have been diffi-
cult if not impossible to obtain by chemical transformations of
natural tetracyclines (‘semisynthetic’ processes). A key enablement
that permitted the development of this streamlined route was the
introduction by Stork and Hagedorn of the 3-benzyloxyisoxazole
function as a masked form of the vinylogous carbamic acid of the
A ring of tetracyclines, a protective group that is readily cleaved by
hydrogenolysis.3 It is therefore appropriate that the present report,
in which we build upon our earlier work through methodological
advances that permit for the first time modification of position C5a
of the tetracycline scaffold, appear in this special publication ded-
icated to Professor Gilbert Stork, a pioneering investigator in syn-
thetic organic chemistry of extraordinary accomplishment.fas.harvard.edu (P.M.Wright),
All rights reserved.Previous work has demonstrated that our fully synthetic ap-
proach to tetracyclines allows modifications at positions C6eC10
that are not feasible by semisynthesis.1,2 One area of focus in our
current research is the development of chemical pathways that
enable modifications at other positions, such as C5a, that have not
previously been viable. Position C5a is one of two points of fusion of
the B and C rings of tetracyclines and, as such, substitution of this
position gives rise to a quaternary carbon center. Inspection of
X-ray crystallographic data of tetracycline bound to the 30S subunit
of the ribosome of Thermus Thermophilus suggests that substitution
of position C5a would not obviously impede ribosome binding and
thus could present an interesting and unexplored avenue for the
discovery of potential new antibiotics to address problems such as
bacterial resistance.4,5 To apply our general route for tetracycline
synthesis to C5a-substituted analogs it was first necessary to de-
velop methodology to prepare AB enones containing different
b-substituents, and then to determine if these modified AB enones
would successfully undergo MichaeleClaisen cyclization reactions
with D-ring precursors, transformations that would give rise to
a quaternary, stereogenic center at position C5a. Themost rapid and
straightforward approach to the synthesis of b-substituted AB
enones appeared to be the direct functionalization of the AB enone
1. While introduction of simple alkyl groups such as b-methyl
Fig. 1. Structurally diverse, fully synthetic tetracyclines, now incorporating angular substitution of position C5a.
P.M. Wright, A.G. Myers / Tetrahedron 67 (2011) 9853e98699854proved to be relatively straightforward (though low-yielding), in-
troduction of more highly oxidized b-substituents was less so, and
provided us with the opportunity to pursue a number of chemical
innovations, which we detail herein. The subsequent stereo-
controlled construction of the C ring, comprising an all-carbon
quaternary center at position C5a, was viewed to be a challenging
transformation, and its successful implementation we view to be
a significant advance. During the course of our investigations we
also serendipitously discovered a C5aeC11a bridged cyclopropane-
containing tetracycline intermediate that has proven to be an
extraordinarily versatile precursor to a diverse array of C5a-
substituted tetracyclines, providing another avenue for the syn-
thesis of this novel class of substituted tetracycline antibiotics.Scheme 1. Two-step syntheses of modified AB enones with methyl, methyl ester, trifluoroe
enone 1.2. Results and discussion
2.1. New methods for b-functionalization of enones
As a first step toward the stereocontrolled construction of all-
carbon quaternary, C5a-substituted tetracyclines we first sought
to develop methods to transform the AB enone 1 into b-substituted
AB enones as novel cyclization substrates (Schemes 1e3 below).
A conventional reaction sequence served for the synthesis of the
simple b-methyl-substituted AB enone 3 (Scheme 1). Specifically,
conjugate addition of lithium dimethylcuprate to the AB enone 1 in
the presence of trimethylsilylchloride6 afforded the corresponding
b-methyl-substituted trimethylsilyl enol ether 2 in 85% yield (1D-thyl ester, and thioester groups at the b-position, starting from the b-unsubstituted AB
Scheme 2. Synthesis of the b-methyl ester-substituted AB enone 5 from the b-unsubstituted AB enone 1 in a single operation.
Scheme 3. Two protocols for the synthesis of the b-methoxymethoxymethyl AB enone 10 from the AB enone 1; the first, and more efficient, proceeds via the b-carbaldehyde AB
enone 9.
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accord with all precedent in this system);1 oxidation of this in-
termediate with palladium acetate in dimethyl sulfoxide (DMSO) at
80 C then afforded the b-methyl-substituted AB enone 3 in modest
yield (44% yield on 160-mg scale, and 34% yield on 2.8-g scale).7,8
Attempted oxidation of the intermediate trimethylsilyl enol ether
2 with the alternative oxidant o-iodoxybenzoic acid (IBX) was not
successful.9
To transform the AB enone 1 into b-substituted AB enones with
more highly oxidized b-substituents we were led to explore novel
chemistry, as precedentedmethods were deemed to be too indirect
or were impracticable in the present application.10e12 First, we
developed a versatile sequence for b-functionalization of the AB
enone 1 initiated by conjugate addition of the Seebach reagent
tris(methylthio)methyllithium13 (THF, 78/45 C) followed by
trapping of the resulting enolate at 45 C with chloro-
trimethylsilane.14 The corresponding b-tris(methylthio)methyl tri-
methylsilyl enol ether (4) was isolated as a single stereoisomer
(stereochemistry not determined) in 89% yield after purification by
flash-column chromatography. We found that oxidation of the tri-
methylsilyl enol ether function and transformation of the tris(me-
thylthio)methyl group occurred simultaneously upon treatment of
a solution of 4 in the solvent mixture 500:1 methanol/water with
an excess of N-bromosuccinimide (NBS, 5 equiv) at 23 C, affordingthe AB enone containing a b-methyl ester substituent (5) in 85%
yield. The detailed mechanism of the transformation of the in-
termediate 4 into the b-substituted AB enone 5 is not known, but
presumably involves some variation of a sequence involving a-
bromination of the trimethylsilyl enol ether, bromonium-induced
conversion of the tris(methylthio)methyl substituent into the cor-
responding methyl ester (with incorporation of one molar equiva-
lent each of methanol and water), and elimination of hydrogen
bromide. By modification of the reaction solvent we found that
different esters could be synthesized, including active esters. For
example, addition of NBS (5 equiv) to a solution of the trimethylsilyl
enol ether 4 in 2,2,2-trifluoroethanol and water (500:1 mixture) at
23 C afforded the corresponding b-trifluoroethyl ester-substituted
AB enone 6 in 87% yield. Alternatively, treatment of a solution of
substrate 4 in tert-butanol with NBS (4 equiv) at 23 C afforded the
AB enone 7 bearing an S-methyl thioester at the b-position in 82%
yield.15 The transformations of Schemes 1e3 represent novel, di-
rect, and highly efficient b-functionalization reactions of an enone
substrate. Important foundational precedents include the conver-
sion of a b-cyano-substituted trimethylsilyl enol ether to the cor-
responding b-cyano enone upon sequential treatment with
NBS and triethylamine10a as well as the original discovery that
dithianes undergo oxidative hydrolysis in the presence of
N-halosuccinimides.16
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unsubstituted AB enone 1 to the b-methyl ester-substituted AB
enone 5 could be achieved directly, andmost efficiently (90% yield),
in a single operation (Scheme 2).
A related strategy was effective for the synthesis of the AB enone
9 bearing a b-carbaldehyde substituent, which in turn provided an
expedient route to AB enones with b-alkoxymethyl substituents
(Scheme 3). Thus, conjugate addition of the CoreyeSeebach reagent
2-lithio-1,3-dithiane17 to the AB enone 1 in the presence of hex-
amethylphosphoramide (HMPA)18 at 78 C followed by quench-
ing of the resulting enolate intermediate with chlorotrime-
thylsilane provided the b-(1,3-dithian-2-yl) trimethylsilyl enol
ether 8 as a single stereoisomer (90% yield; stereochemistry not
determined). Treatment of the latter product with NBS (6 equiv) in
the solvent mixture 100:1 tert-butanol/water at 23 C afforded the
b-carbaldehyde AB enone 9 in 90% yield. Selective reduction of the
aldehyde group occurred uponwarming a solution of 9 and sodium
triacetoxyborohydride in benzene at 40 C. The resulting primary
alcohol was then protected as a methoxymethyl ether in the
presence of chloromethyl methyl ether and N,N-diisopropylethyl-
amine in benzene at 50 C to afford the b-methoxymethoxymethyl
AB enone 10 (85% yield over two steps). AB enone 10 could also be
prepared in fewer steps but much lower (and highly variable) yield
by the reaction of the AB enone 1 with (methoxymethoxy)meth-
yllithium (prepared in situ from tri-n-butyl[(methoxymethoxy)Scheme 4. Stereocontrolled formation of an all-carbon quaternary center by MichaeleCmethyl]stannane19 and n-butyllithium) in the presence of HMPA
at 78 C, trapping of the resulting enolate with chloro-
trimethylsilane (affording the b-methoxymethoxymethyl trime-
thylsilyl enol ether 11 in 40e55% yield), and then oxidation of the
intermediate 11 with palladium acetate in DMSO at 50 C (pro-
viding AB enone 10 in 25e52% yield).
2.2. Stereocontrolled construction of all-carbon quaternary
centers by MichaeleClaisen cyclization reactions of b-
substituted AB enones
Having established versatile methodology for the synthesis of
b-substituted AB enone substrates, we next investigated the fea-
sibility of constructing the C ring of tetracyclines with an all-
carbon quaternary C5a stereocenter by a MichaeleClaisen cycli-
zation reaction (Scheme 4). The D-ring precursors 12 (with OBoc
protection at ‘C10’) and 13 (with OBn protection at ‘C10’) were
chosen for initial cyclization experiments. These precursors com-
prise the D-ring functionality of minocycline (Scheme 4) and are
known from prior research to be highly effective substrates in
MichaeleClaisen cyclization reactions.1b Addition of the b-methyl-
substituted AB enone 3 (1 equiv) to a bright red solution of the
o-toluate ester anion formed by deprotonation of the minocycline
D-ring precursor 12 (3 equiv) with lithium diisopropylamide (LDA,
3 equiv) in the presence of N,N,N0,N0-tetramethylethylenediaminelaisen cyclization reactions of o-toluate ester anions with b-substituted AB enones.
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provided the MichaeleClaisen cyclization product 14 in 80% yield
as a single stereoisomer after purification by flash-column chro-
matography. A minor by-product (<5%), thought to be the product
of 1,2-additionecyclization (by lactonization), was isolated sepa-
rately. The stereochemical assignment of the MichaeleClaisen cy-
clization product (14), with C5a-R configuration, is supported by
NOE studies; this stereochemistry is homologous with that of
MichaeleClaisen cyclization products derived from the non-
substituted AB enone 1.1,2 In both cases, addition appears to oc-
cur from a single diastereoface of the enone, that opposite the
C12a tert-butyldimethylsilyloxy substituent.1b There are two ex-
amples in the literature of MichaeleClaisen cyclization reactions of
achiral b-methyl cyclohexenones with o-toluate ester anions,20 but
we are unaware of any examples beyond those described here of
the stereocontrolled construction of a six-membered ring con-
taining a quaternary center by a MichaeleClaisen cyclization
reaction.
MichaeleClaisen reaction of the b-methoxymethoxymethyl AB
enone 10 and the minocycline D-ring precursor 13 (chosen so as to
allow later deprotection of the methoxymethyl ether at C5a
without concomitant cleavage of the C10 phenoxy protective
group) was also efficient, affording the cyclization product 15, with
a protected C5a-hydroxymethyl-substituted quaternary center, in
72% yield (Scheme 4). Reaction of the b-methyl ester AB enone 5
with the anion formed from the minocycline D-ring precursor 12
afforded a complex mixture of products containing the desired
MichaeleClaisen cyclization product 16 as one component.
Cycloadduct 16 was isolated in 23% yield after purification by se-
quential flash-column chromatography and reverse-phase high-
performance liquid chromatography (rp-HPLC). Two-step depro-
tection of cyclization products 14 and 16 under typical condi-
tions1,3 provided C5a-methylminocycline (17, 100% yield,
Scheme 5) and C5a-carbomethoxyminocycline (18, 89% yield),
respectively, after purification by rp-HPLC. Thus, hydrogenolytic
deprotection of the 3-benzyloxyisoxazole function, as reported byScheme 5. Synthesis of C5a-methylminocycline (17) and C5a-carbomethoxyminocycli
Scheme 6. Discovery of a C5aeC11a-bridgedStork and Hagedorn,3 reveals the vinylogous carbamic acid func-
tion of the A ring of tetracyclines in the final step of the synthetic
sequence.
2.3. Discovery and diversification of a C5aeC11a bridged
cyclopropane-containing tetracycline intermediate
In a search for a versatile branch point for the synthesis of
various C5a-substituted tetracyclines we were led to a serendipi-
tous but highly effective solution (Scheme 6). Removal of the
methoxymethyl ether protective group within the Michaele-
Claisen cyclization product 15 was achieved by treatment with
perchloric acid (CAUTION!),21 providing the substituted neopentyl
alcohol 19 (73% yield). Addition of phosgene to a solution of 19 in
dichloromethane/pyridine (10:1) at 0 C unexpectedly afforded
the C5aeC11a-bridged cyclopropane tetracycline precursor 20 in
81% yield. After the fact, the formation of 20 is easily rationalized.
In this context it is interesting to note that Barton et al. had pre-
viously reported that the (C11,C12) 1,3-diketone can participate in
an internal nucleophilic addition, albeit in that case with addition
to an electrophilic carbonyl group that had been introduced at
position C4.22
Cyclopropanes with geminal electron-withdrawing substituents
are known to undergo nucleophilic ring-opening,23 a trans-
formation often enhanced in the presence of Lewis acids.24 We
were led to explore the use of magnesium salts as Lewis acid ac-
tivators in this system in view of the well documented affinity of
Mg2þ for binding to the (C11,C12) 1,3-diketone function of tetra-
cyclines, complexation which is critical for inhibition of the ribo-
some.4 We observed that the bridged cyclopropane intermediate
20 underwent regioselective ring-opening at the bridging carbon
atom in the presence of various nucleophiles and magnesium
bromide as Lewis acid. The ring-opened products were readily
deprotected in the typical two-step sequence to furnish the cor-
responding C5a-substituted tetracyclines (Table 1). For example,
reaction of the C5aeC11a-bridged cyclopropane tetracyclinene (18) by two-step deprotection of cyclization products 14 and 16, respectively.
cyclopropane tetracycline precursor (20).
Table 1
Fully synthetic tetracyclines prepared from the C5aeC11a bridged cyclopropane intermediate 20 by magnesium bromide-promoted ring-opening followed by two-step
deprotection
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chiometric amount of anhydrous magnesium bromide in THF at
23 C, followed by direct deprotection of the crude ring-opened
product (21), provided C5a-pyrrolidinomethylminocycline (22) in
74% yield over the three steps after purification by rp-HPLC. A
number of different amines and alcohols were found to function
effectively as nucleophiles in the magnesium bromide-promoted
cyclopropane ring-opening reaction (Table 1). Ring-opening re-
actions were typically performed with a large excess of nucleophile
(7 equiv) and stoichiometric or superstoichiometric quantities of
anhydrous magnesium bromide in THF (in the cases of low mo-
lecular weight alcohols as nucleophiles, the alcohol was used as
solvent) at a range of temperatures (23e75 C, see Experimental
section for details). Partial (and inconsequential) loss of the ben-
zyl ether phenolic protective group was observed to occur in the
cyclopropane ring-opening reaction in some instances.
The C5aeC11a-bridged cyclopropane intermediate 20 also
served as a precursor to tetracyclines with aminomethyl (32) and
piperazinylmethyl (34) substituents at position C5a (Scheme 7),
highly versatile compounds which functioned as further branch-
points for the synthesis of C5a-substituted tetracyclines (Figs. 2
and 3). Thus, treatment of cyclopropane 20 with sodium azide in
dimethylformamide at 23 C afforded the azido-substituted ring-
opened product 31 in 78% yield after purification by flash-column
chromatography.25 Addition of trimethylphosphine (2 equiv) to
a solution of the azide 31 and 2-(tert-butoxycarbonyloxyimino)-2-
phenylacetonitrile (BoceON, 2 equiv) in THF at 10 C followed by
warming to 23 C afforded the corresponding tert-butyl carbamate
(51% yield).26 Two-step deprotection of the tert-butyl carbamate
intermediate was best achieved by an inverted deprotection se-
quence (hydrogenolysis followed by treatment with hydrofluoric
acid),27 providing C5a-aminomethylminocycline 32 after purifica-
tion by rp-HPLC (69% yield over two steps). In addition, magnesiumbromide-promoted ring-opening of cyclopropane 20 with N-tert-
butoxycarbamyl-piperazine followed by deprotection of the ring-
opened product 33 provided C5a-piperazinylmethylminocycline
(34, 58% yield over three steps). Final-step diversification of 32
and 34 was readily achieved, affording a range of novel tetracy-
clines with C5a substituents incorporating amides, sulfonamides,
and amines (Figs. 2 and 3). In this manner the C5aeC11a-bridged
cyclopropane 20 served as a common precursor for the synthesis of
more than 25 structural variants of minocycline with a diverse
range of substituents at C5a.
3. Conclusion
Synthetic methodological advances have permitted efficient and
stereocontrolled construction of diverse fully synthetic tetracy-
clines containing an all-carbon quaternary center at position C5a.
These examples serve to further demonstrate the broad applica-
bility of the MichaeleClaisen cyclization reaction as a powerful
method for the assembly of stereochemically complex six-
membered rings.28 New strategies presented herein for the in-
troduction of ester, thioester, and aldehyde substituents at the
b-position of cyclohexenones are anticipated to be of value in many
contexts. The discovery of a highly diversifiable bridged
cyclopropane-containing tetracycline intermediate enabled effi-
cient synthesis of numerous C5a-substituted tetracyclines, a struc-
turally novel class of compounds in this important family of
therapeutic agents. Although it is conceivable that many of these
structures could also have been accessed by MichaeleClaisen cy-
clization reactions of individually prepared b-substituted AB
enones, the discovery of a diversifiable late-stage intermediate
greatly expedited the process of synthesis, in that a single
MichaeleClaisen cycloadduct served as a precursor to large num-
bers of C5a-substituted tetracyclines. The success of the C-ring-
Fig. 2. Fully synthetic tetracyclines prepared by final-step diversification of C5a-aminomethylminocycline (32).
Scheme 7. Synthesis of substrates for final-step diversification from cyclopropane 20.
P.M. Wright, A.G. Myers / Tetrahedron 67 (2011) 9853e9869 9859forming cyclization reactions of b-substituted AB enones described
herein, combined with the extraordinary number and diversity of
D-ring precursors known to be effective nucleophiles in this key
coupling reaction, implies that a multiplicative expansion of theFig. 3. Fully synthetic tetracyclines prepared by final-step dipool of fully synthetic tetracyclines is achievable, in the sense that
each modified AB enone could in theory be coupled with the
hundreds of different D-ring precursors that have been found to be
effective coupling partners with the AB enone 1.versification of C5a-piperazinylmethylminocycline (34).
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4.1. General experimental procedures
All reactions were performed in round-bottom flasks fitted with
rubber septa under a positive pressure of argon, unless otherwise
noted. Air- and moisture-sensitive liquids were transferred via sy-
ringe or stainless steel cannula. Organic solutions were concen-
trated by rotary evaporation (house vacuum, ca. 25e40 Torr) at
ambient temperature, unless otherwise noted. Analytical thin-layer
chromatography (TLC) was performed using glass plates pre-coated
with silica gel (0.25 mm, 60A pore-size, 230e400 mesh, Merck
KGA) impregnatedwith a fluorescent indicator (254 nm). TLC plates
were visualized by exposure to ultraviolet light, then were stained
with aqueous potassium permanganate solution. Flash-column
chromatography was performed as described by Still et al.,29
employing silica gel (60A, 32e63 mm, standard grade, Dynamic
Adsorbents, Inc.).
Materials. Commercial solvents and reagents were used as re-
ceived with the following exceptions. Diisopropylamine, TMEDA,
chlorotrimethylsilane, and hexamethylphosphoramide were dis-
tilled from calcium hydride under an atmosphere of argon or
dinitrogen. Tetrahydrofuran was purified by the method of Pang-
born et al.30 The molarity of n-butyllithium solutions was de-
termined by titration against a standard solution of diphenylacetic
acid in tetrahydrofuran (average of three determinations).31
Instrumentation. Proton magnetic resonance (1H NMR) spectra
were recorded on Varian INOVA 400 (400 MHz), 500 (500 MHz) or
600 (600 MHz) NMR spectrometers at 23 C. Proton chemical shifts
are expressed in parts per million (ppm, d scale) and are referenced
to residual protium in the NMR solvent (CHCl3, d 7.26). Data are
represented as follows: chemical shift, multiplicity (s¼singlet,
d¼doublet, t¼triplet, q¼quartet, m¼multiplet and/or multiple
resonances, br¼broad), integration, and coupling constant (J) in
hertz. Carbon nuclear magnetic resonance spectra (13C NMR) were
recorded on Varian INOVA 500 (125 MHz) NMR spectrometers at
23 C. Carbon chemical shifts are expressed in parts per million
(ppm, d scale) and are referenced to the carbon resonance of the
NMR solvent (CDCl3, d 77.0). Infrared (IR) spectra were obtained
using a Shimadzu 8400S FT-IR spectrometer andwere referenced to
a polystyrene standard. Data are represented as follows: frequency
of absorption (cm1), intensity of absorption (s¼strong,
m¼medium, w¼weak, br¼broad). High-resolution mass spectra
were obtained at theHarvardUniversityMass Spectrometry Facility.
4.2. Experimental procedures
4.2.1. b-Methyl-substituted trimethylsilyl enol ether 2. A round-
bottomed flask charged with copper (I) iodide (1.89 g, 9.95 mmol,
1.6 equiv) was flame-dried under high vacuum. After cooling to
room temperature, the flask was blanketed with dry argon. Tetra-
hydrofuran (50 mL) was added and the resulting suspension was
cooled to 0 C. A solution of methyllithium in ethyl ether (1.6 M,
12.2 mL, 19.6 mmol, 3.15 equiv) was added dropwise via syringe
over 5 min. The resulting solution was stirred at 0 C for 20 min,
then was cooled to 78 C. A solution of the AB enone 1 (3.0 g,
6.22 mmol, 1 equiv) and chlorotrimethylsilane (1.25 mL,
9.95 mmol, 1.6 equiv) in tetrahydrofuran (10 mL) was added to the
cuprate solution dropwise via syringe at 78 C. After stirring
at 78 C for 90 min, the cooling bath was removed and the
product solution was diluted with ethyl acetate (100 mL) and
hexanes (100 mL). A mixture of saturated aqueous ammonium
chloride solution and saturated aqueous ammonium hydroxide
solution (19:1, 100 mL) was then added carefully. The phases were
separated and the organic phase was washed sequentially with
saturated aqueous ammonium chloride solution (100 mL) andsaturated aqueous sodium chloride solution (2100 mL). The or-
ganic phase was dried over anhydrous sodium sulfate. The dried
solutionwas filtered and the filtrate was concentrated. The product
was purified by flash-column chromatography (7% ethyl acetate/
hexanes), providing b-methyl-substituted trimethylsilyl enol ether
2 as awhite solid (3.01 g, 85%). Rf¼0.57 (15% ethyl acetate/hexanes);
1H NMR (500 MHz, CDCl3) d 7.48 (dd, 2H, J¼8.0, 1.5 Hz), 7.36e7.31
(m, 3H), 5.36 (AB quartet, 2H), 4.69 (d, 1H, J¼3.0 Hz), 3.76 (d, 1H,
J¼10.0 Hz), 2.55e2.52 (m, 1H), 2.44 (s, 6H), 2.32e2.25 (m, 2H), 1.84
(d, 1H, J¼13.5 Hz), 1.18 (d, 3H, J¼7.5 Hz), 0.87 (s, 9H), 0.22 (s, 3H),
0.11 (s, 3H), 0.04 (s, 9H); 13C NMR (125 MHz, CDCl3) d 189.7, 181.5,
167.4, 147.2, 135.2, 128.6, 128.5, 128.4, 110.7, 108.3, 80.7, 72.2, 61.1,
46.3, 41.9, 26.2, 26.0, 25.1, 24.0, 18.8, 0.5, 2.8, 3.6; FTIR (neat
film), 2955 (w), 1721 (m), 1653 (w), 1614 (w), 1510 (m), 1471 (w),
1250 (m), 1198 (m), 1148 (m), 936 (m), 833 (s) cm1; HRMSeESI (m/
z): [MþH]þ calcd for C30H47N2O5Si2, 571.3018; found, 571.3041.
4.2.2. b-Methyl-substituted AB enone 38. Palladium (II) acetate
(75 mg, 0.329 mmol, 1.15 equiv) was added to a solution of
b-methyl-substituted trimethylsilyl enol ether 2 (163 mg,
0.286 mmol, 1 equiv) in anhydrous dimethyl sulfoxide (3.0 mL) at
23 C. The resulting mixture was heated to 80 C. After stirring at
this temperature for 16 h, the reaction mixture was allowed to cool
to 23 C. The cooled suspension was diluted with ethyl acetate
(20 mL) and thewholewas filtered through a pad of Celite. Hexanes
(20 mL) were added to the filtrate and the resulting solution was
washed sequentially with saturated aqueous sodium bicarbonate
solution (20 mL) and saturated aqueous sodium chloride solution
(220 mL). The organic phase was dried over anhydrous sodium
sulfate. The dried solution was filtered and the filtrate was con-
centrated. The product was purified by flash-column chromatog-
raphy (10% ethyl acetate/hexanes), affording the b-methyl-
substituted AB enone 3 as a pale yellow solid (63 mg, 44%). Rf¼0.26
(15% ethyl acetate/hexanes); 1H NMR (500 MHz, CDCl3) d 7.50 (d,
2H, J¼7.0 Hz), 7.40e7.32 (m, 3H), 5.93 (s, 1H), 5.35 (AB quartet, 2H),
3.74 (d, 1H, J¼11.0 Hz), 2.81e2.70 (m, 3H), 2.46 (s, 6H), 2.01 (s, 3H),
0.82 (s, 9H), 0.26 (s, 3H), 0.05 (s, 3H); 13C NMR (125 MHz, CDCl3)
d 193.1, 188.1, 181.2, 167.5, 161.2, 135.0, 128.5, 128.5, 124.7, 108.4,
82.5, 72.5, 59.8, 47.5, 42.0, 30.4, 25.9, 24.4, 19.0, 2.5, 4.2; FTIR
(neat film), 2930 (w), 1719 (s), 1672 (m), 1510 (m), 1472 (w), 1175
(m), 1045 (m), 936 (s), 829 (m) cm1; HRMSeESI (m/z): [MþH]þ
calcd for C27H37N2O5Si, 497.2466; found, 497.2494.
4.2.3. b-Tris(methylthio)methyl trimethylsilyl enol ether 4. A solu-
tion of n-butyllithium in hexanes (2.5 M, 518 mL, 1.30 mmol,
1.25 equiv) was added dropwise via syringe to a solution of tris(-
methylthio)methane (176 mL, 1.30 mmol, 1.25 equiv) in tetrahy-
drofuran (11 mL) at 78 C. The resulting colorless solution was
stirred at this temperature for 20 min, whereupon a solution of the
AB enone 1 (500 mg, 1.04 equiv, 1 equiv) in tetrahydrofuran
(3.0 mL) was added dropwise via syringe, forming a bright orange-
yellow solution. The reaction solution was allowed to warm slowly
to 45 C over 60 min, then chlorotrimethylsilane (199 mL,
1.55 mmol, 1.5 equiv) was added. The (yellow) reaction mixture
was stirred at 45 C for 30 min, then was partitioned between
aqueous potassium phosphate buffer solution (pH 7.0, 0.2 M,
20 mL) and dichloromethane (30 mL). The phases were separated
and the aqueous phase was extracted with dichloromethane
(20 mL). The organic extracts were combined and the combined
solution was dried over anhydrous sodium sulfate. The dried so-
lution was filtered and the filtrate was concentrated, affording an
orange-yellow oil. The crude product was purified by flash-column
chromatography (6% ethyl acetate/hexanes), providing b-tris(me-
thylthio)methyl trimethylsilyl enol ether 4 as a pale yellow foam
(654 mg, 89%). Rf¼0.69 (20% ethyl acetate/hexanes); 1H NMR
(500 MHz, CDCl3) d 7.49e7.47 (m, 2H), 7.37e7.32 (m, 3H), 5.37 (AB
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(m, 1H), 2.52 (dd, 1H, J¼14.4, 4.2 Hz), 2.45 (s, 6H), 2.42e2.39 (m,
1H), 2.18 (s, 9H), 2.14e2.06 (m, 1H), 0.86 (s, 9H), 0.22 (s, 3H), 0.12 (s,
3H), 0.01 (s, 9H); 13C NMR (125 MHz, CDCl3) d 189.6, 181.6, 167.2,
150.5, 135.2, 128.6, 128.5, 128.4, 108.7, 103.8, 81.6, 75.1, 72.2, 61.7,
46.6, 42.1, 41.7, 26.1, 21.2, 19.0, 14.1, 0.3, 2.6, 3.3; FTIR (neat
film), 1722 (m), 1651 (w), 1614 (w), 1510 (m), 1472 (w), 1254 (m),
1206 (w), 903 (m), 839 (s) cm1; HRMSeESI (m/z): [MþH]þ calcd
for C33H53N2O5S3Si2, 709.2650; found, 709.2617.
4.2.4. b-Methyl ester-substituted AB enone 5. N-Bromosuccinimide
(151 mg, 0.846 mmol, 5.0 equiv) was added in one portion to
a stirring solution of b-tris(methylthio)methyl trimethylsilyl enol
ether 4 (120 mg, 0.169 mmol, 1 equiv) in methanol (4.5 mL) and
water (9.0 mL, 3.0 equiv, 500:1 mixture of methanol and water) at
23 C. The pale yellow reaction solutionwas allowed to stir at 23 C
for 30 min, then was concentrated. The resulting yellow oil was
dissolved in dichloromethane (20 mL) and the resulting solution
was washed with saturated aqueous sodium bicarbonate solution
(20 mL). The phases were separated and the aqueous phase was
extractedwith dichloromethane (20 mL). The organic extracts were
combined and the combined solution was dried over anhydrous
sodium sulfate. The dried solution was filtered and the filtrate was
concentrated. The crude product was purified by flash-column
chromatography (11% ethyl acetate/hexanes, grading to 15%), pro-
viding the b-methyl ester-substituted AB enone 5 as a yellow solid
(78 mg, 85%). Rf¼0.26 (15% ethyl acetate/hexanes); 1H NMR
(500 MHz, CDCl3) d 7.50 (d, 2H, J¼6.9 Hz), 7.40e7.33 (m, 3H), 6.82
(d, 1H, J¼1.8 Hz), 5.36 (AB quartet, 2H), 3.87 (s, 3H), 3.65 (d, 1H,
J¼10.5 Hz), 3.21 (d, 1H, J¼18.8 Hz), 2.91e2.84 (m, 2H), 2.46 (s, 6H),
0.80 (s, 9H), 0.26 (s, 3H), 0.03 (s, 3H); 13C NMR (125 MHz, CDCl3)
d 194.2, 187.0, 181.1, 167.4, 166.1, 147.1, 134.9, 131.4, 128.6, 128.5,
128.5, 108.3, 82.5, 72.6, 59.3, 52.9, 47.2, 41.9, 25.9, 24.6, 19.0, 2.5,
4.1; FTIR (neat film), 1721 (s), 1684 (m), 1609 (w), 1510 (m), 1252
(m), 1173 (m), 1030 (m), 831 (m), 737 (m) cm1; HRMSeESI (m/z):
[MþH]þ calcd for C28H37N2O7Si, 541.2365; found, 541.2368.
4.2.5. b-Methyl ester-substituted AB enone 5 (single-operation
method). A solution of n-butyllithium in hexanes (2.5 M, 104 mL,
0.259 mmol, 1.25 equiv) was added dropwise via syringe to a solu-
tion of tris(methylthio)methane (35.2 mL, 0.259 mmol, 1.25 equiv)
in tetrahydrofuran (2.0 mL) at 78 C. The resulting colorless so-
lution was stirred at this temperature for 20 min, whereupon a so-
lution of the AB enone 1 (100 mg, 0.207 mmol, 1 equiv) in
tetrahydrofuran (0.4 mL) was added dropwise via syringe, forming
a bright orange-yellow solution. The reaction solution was allowed
to warm slowly to 45 C over 30 min, then chlorotrimethylsilane
(39.7 mL, 0.311 mmol, 1.5 equiv) was added. The resulting (yellow)
mixture was allowed to warm to 23 C over 30 min, whereupon
methanol (4.0 mL), water (8.0 mL, 2.1 equiv, 500:1 mixture of
methanol and water) and N-bromosuccinimide (221 mg,
1.24 mmol, 6.0 equiv) were added in sequence. The reaction mix-
ture was allowed to stir at 23 C for 30 min, thenwas concentrated.
The resulting oily (yellow) suspension was dissolved in dichloro-
methane (15 mL) and the resulting solution was washed with sat-
urated aqueous sodium bicarbonate solution (15 mL). The phases
were separated and the aqueous phase was extracted with
dichloromethane (15 mL). The organic extracts were combined and
the combined solution was dried over anhydrous sodium sulfate.
The dried solution was filtered and the filtrate was concentrated.
The crude product was purified by flash-column chromatography
(7% acetone/hexanes), providing the b-methyl ester-substituted AB
enone 5 as a yellow solid (101 mg, 90%).
4.2.6. b-Trifluoroethyl ester-substituted AB enone 6. N-Bromosucci-
nimide (100 mg, 0.564 mmol, 5.0 equiv)was added in one portion toa stirring solution of b-tris(methylthio)methyl trimethylsilyl enol
ether 4 (80 mg, 0.113 mmol, 1 equiv) in 2,2,2-trifluoroethanol
(3.0 mL) and water (6.0 mL, 500:1 mixture of 2,2,2-trifluoroethanol
and water) at 23 C. The bright orange reaction solution was
allowed to stir at 23 C for 45 min, then was concentrated. The
resulting yellow oil was dissolved in dichloromethane (20 mL) and
the resulting solution was washed with saturated aqueous sodium
bicarbonate solution (20 mL). The phases were separated and the
aqueous phase was extracted with dichloromethane (20 mL). The
organic extracts were combined and the combined solution was
dried over anhydrous sodium sulfate. The dried solutionwas filtered
and the filtrate was concentrated. The crude product was purified by
flash-column chromatography (10% ethyl acetate/hexanes), pro-
viding the b-trifluoroethyl ester-substituted AB enone 6 as a yellow
solid (60 mg, 87%). Rf¼0.33 (15% ethyl acetate/hexanes); 1H NMR
(500 MHz, CDCl3) d 7.50 (d, 2H, J¼6.9 Hz), 7.41e7.35 (m, 3H), 6.90 (d,
1H, J¼2.3 Hz), 5.36 (AB quartet, 2H), 4.68e4.62 (m, 2H), 3.65 (d, 1H,
J¼11.0 Hz), 3.22 (d, 1H, J¼18.8 Hz), 2.95e2.87 (m, 2H), 2.47 (s, 6H),
0.80 (s, 9H), 0.27 (s, 3H), 0.04 (s, 3H); 13C NMR (125 MHz, CDCl3)
d194.0,186.7,181.0,167.4,164.1,145.2,134.9,132.7,128.6,128.5,128.5,
122.5 (q, J¼276.5 Hz), 108.3, 82.4, 72.7, 61.3 (q, J¼37.5 Hz), 59.3, 47.0,
41.9, 25.9, 24.5, 18.9, 2.5, 4.1; FTIR (neat film), 1742 (m), 1721 (s),
1688 (m),1607 (w),1510 (m),1167 (s), 936 (s) cm1;HRMSeESI (m/z):
[MþH]þ calcd for C29H36F3N2O7Si, 609.2238; found, 609.2299.
4.2.7. b-S-Methyl thioester-substituted AB enone 7. N-Bromosucci-
nimide (48 mg, 0.271 mmol, 4.0 equiv) was added in one portion to
a stirring solution of b-tris(methylthio)methyl trimethylsilyl enol
ether 4 (48 mg, 0.068 mmol, 1 equiv) in tert-butanol (3.0 mL) at
23 C. The resulting bright yellow suspension was allowed to stir at
23 C for 45 min (slowly clearing to give a yellow solution). The
reactionmixturewas dilutedwith dichloromethane (20 mL) and the
resulting solution was washed with saturated aqueous sodium bi-
carbonate solution (20 mL). The phases were separated and the
aqueous phase was extracted with dichloromethane (20 mL). The
organic extracts were combined and the combined solution was
dried over anhydrous sodium sulfate. The dried solutionwas filtered
and the filtrate was concentrated. The crude product was purified by
flash-column chromatography (8% ethyl acetate/hexanes), providing
the b-S-methyl thioester-substituted AB enone 7 as a pale yellow
solid (31 mg, 82%). Rf¼0.51 (20% ethyl acetate/hexanes); 1H NMR
(500 MHz, CDCl3) d 7.51e7.50 (m, 2H), 7.41e7.35 (m, 3H), 6.72 (d,1H,
J¼2.4 Hz), 5.36 (AB quartet, 2H), 3.70 (d, 1H, J¼10.7 Hz), 3.30 (d, 1H,
J¼19.5 Hz), 2.98e2.93 (m, 1H), 2.89 (dd, 1H, J¼10.5, 3.7 Hz), 2.49 (s,
6H), 2.45 (s, 3H), 0.82 (s, 9H), 0.26 (s, 3H), 0.05 (s, 3H); 13C NMR
(125 MHz, CDCl3) d 194.2, 192.9, 186.8, 181.0, 167.4, 153.2, 134.9,
128.6, 128.5, 128.5, 127.8, 108.3, 82.6, 72.6, 59.3, 47.3, 41.9, 25.9, 25.9,
24.4, 19.0, 11.9, 2.5, 4.0; FTIR (neat film), 1721 (m), 1684 (w), 1661
(w), 1510 (m), 1136 (w), 1040 (m), 937 (s), 735 (s) cm1; HRMSeESI
(m/z): [MþH]þ calcd for C28H37N2O6SSi, 557.2136; found, 557.2109.
4.2.8. b-(1,3-Dithian-2-yl) trimethylsilyl enol ether 8. A solution of
n-butyllithium in hexanes (2.5 M, 2.91 mL, 7.27 mmol, 1.15 equiv)
was added to a solution of 1,3-dithiane (862 mg, 6.95 mmol,
1.1 equiv) in tetrahydrofuran (60 mL) at 78 C. The resulting so-
lution was stirred at this temperature for 30 min, at which point
hexamethylphosphoramide (2.44 mL, 13.9 mmol, 2.2 equiv) was
added dropwise. After stirring at 78 C for a further 2 min, a so-
lution of the AB enone 1 (3.05 g, 6.32 mmol, 1 equiv) in tetrahy-
drofuran (15 mL) was added to the reaction solution dropwise via
syringe. The brownish-yellow reaction mixture was stirred at
78 C for 40 min whereupon chlorotrimethylsilane (1.20 mL,
9.48 mmol, 1.5 equiv) was added. After stirring at 78 C for
40 min, aqueous potassium phosphate buffer solution (pH 7.0,
0.2 M, 100 mL) was added to the reaction solution. The resulting
mixture was allowed to warm to 23 C, then was extracted with
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and the combined solution was dried over anhydrous sodium sul-
fate. The dried solution was filtered and the filtrate was concen-
trated. The product was purified by flash-column chromatography
(8% ethyl acetate/hexanes), affording b-(1,3-dithian-2-yl) trime-
thylsilyl enol ether 8 as a white foam (3.85 g, 90%). Rf¼0.53 (30%
ethyl acetate/hexanes); 1H NMR (500 MHz, CDCl3) d 7.48 (d, 2H,
J¼7.0 Hz), 7.38e7.31 (m, 3H), 5.36 (AB quartet, 2H), 4.98 (d, 1H,
J¼3.0 Hz), 4.12 (d, 1H, J¼5.0 Hz), 3.89 (d, 1H, J¼9.5 Hz), 2.96e2.82
(m, 5H), 2.46 (s, 6H), 2.34e2.29 (m, 1H), 2.28e2.23 (m, 2H),
2.15e2.09 (m, 1H), 1.90e1.80 (m, 1H), 0.86 (s, 9H), 0.21 (s, 3H), 0.10
(s, 3H), 0.01 (s, 9H); 13C NMR (125 MHz, CDCl3) d 189.4, 181.5,
167.3, 149.5, 135.1, 128.7, 128.5, 128.4, 108.5, 104.8, 81.0, 72.3, 61.3,
54.9, 46.1, 41.9, 37.1, 31.1, 30.8, 26.1, 25.7, 21.8, 18.9,0.4,2.7,3.6;
FTIR (neat film), cm1 2953 (w), 1721 (s), 1653 (w), 1614 (w), 1510
(s), 1472 (w), 1454 (w), 1254 (s), 1204 (w), 1150 (w), 1024 (w), 934
(s), 901 (s), 835 (s); HRMSeESI (m/z): [MþH]þ calcd for
C33H51N2O5S2Si2, 675.2772; found, 675.2783.
4.2.9. b-Carbaldehyde AB enone 9. N-Bromosuccinimide (158 mg,
0.889 mmol, 6.0 equiv) was added in one portion to a stirring so-
lution of b-(1,3-dithian-2-yl) trimethylsilyl enol ether 8 (100 mg,
0.148 mmol, 1 equiv) in tert-butanol (4.0 mL) and water (40 mL) at
23 C. The reaction mixture was stirred at this temperature for 1 h,
then was partitioned between dichloromethane (20 mL) and sat-
urated aqueous sodium bicarbonate solution (20 mL). The phases
were separated and the aqueous phase was extracted with
dichloromethane (20 mL). The organic extracts were combined and
the combined solution was dried over anhydrous sodium sulfate.
The dried solution was filtered and the filtrate was concentrated.
The crude product was purified by flash-column chromatography
(12% ethyl acetate/hexanes), affording the b-carbaldehyde AB
enone 9 as a yellow solid (68 mg, 90%). Rf¼0.18 (15% ethyl acetate/
hexanes); 1H NMR (500 MHz, CDCl3) d 9.82, (s, 1H), 7.50 (d, 2H,
J¼6.9 Hz), 7.41e7.35 (m, 3H), 6.66 (d, 1H, J¼2.7 Hz), 5.36 (AB
quartet, 2H), 3.58 (d,1H, J¼11.0 Hz), 3.17 (d,1H, J¼19.7 Hz), 2.90 (dd,
1H, J¼10.8, 4.8 Hz), 2.77e2.71 (m,1H), 2.44 (s, 6H), 0.78 (s, 9H), 0.27
(s, 3H), 0.05 (s, 3H); 13C NMR (125 MHz, CDCl3) d 194.6, 193.4, 186.5,
181.2, 167.4, 152.5, 137.2, 134.9, 128.6, 128.5, 128.5, 108.3, 83.2, 72.7,
59.4, 47.0, 41.8, 25.9, 21.5, 19.0, 2.5, 4.0; FTIR (neat film), 1721
(m), 1694 (m), 1607 (w), 1510 (m), 1173 (w), 1036 (m), 937 (s), 737
(s) cm1; HRMSeESI (m/z): [MþH]þ calcd for C27H35N2O6Si,
511.2259; found, 511.2286.
4.2.10. b-Methoxymethoxymethyl AB enone 10. Sodium triacetox-
yborohydride (205 mg, 0.918 mmol, 3.5 equiv) was added in one
portion to a solution of the b-carbaldehyde AB enone 9 (134 mg,
0.262 mmol, 1 equiv) in benzene (2.0 mL) at 23 C. The resulting
solution was heated to 40 C. After stirring at 40 C for 5 ½ h, the
reaction mixture was allowed to cool to 23 C. The cooled solution
was diluted with dichloromethane (30 mL), and the resulting so-
lutionwas added slowly and carefully to saturated aqueous sodium
bicarbonate solution (30 mL). The phases were separated and the
aqueous phase was extracted with dichloromethane (30 mL). The
organic extracts were combined and the combined solution was
dried over anhydrous sodium sulfate. The dried solution was fil-
tered and the filtrate was concentrated.N,N-Diisopropylethylamine
(229 mL, 1.31 mmol, 5.0 equiv) and chloromethyl methyl ether
(59.8 mL, 0.787 mmol, 3.0 equiv) were added sequentially to a so-
lution of the crude reduction product in benzene (1.5 mL) at 23 C.
The reaction flask was sealed and the solution was heated to 50 C.
After stirring at 50 C for 24 h, the reaction mixture was allowed to
cool to 23 C. The cooled solution was partitioned between
dichloromethane (30 mL) and saturated aqueous sodium bi-
carbonate solution (30 mL). The layers were separated and the
aqueous phase was extracted with dichloromethane (30 mL). Theorganic extracts were combined and the combined solution was
dried over anhydrous sodium sulfate. The dried solution was fil-
tered and the filtrate was concentrated, affording an orange oil. The
product was purified by flash-column chromatography (15% ethyl
acetate/hexanes, grading to 17% ethyl acetate/hexanes), providing
the b-methoxymethoxymethyl AB enone 10 as a pale yellow solid
(124 mg, 85% yield, two steps). Rf¼0.40 (30% ethyl acetate/hex-
anes); 1H NMR (500 MHz, CDCl3) d 7.50 (d, 2H, J¼7.0 Hz), 7.40e7.32
(m, 3H), 6.21 (s, 1H), 5.35 (AB quartet, 2H), 4.67 (AB quartet, 2H),
4.16 (m, 2H), 3.74 (d, 1H, J¼10.0 Hz), 3.38 (s, 3H), 2.80e2.74 (m, 3H),
2.45 (s, 6H), 0.82 (s, 9H), 0.26 (s, 3H), 0.05 (s, 3H); 13C NMR
(125 MHz, CDCl3) d 193.1, 187.7, 181.1, 167.5, 159.7, 135.0, 128.5,
128.5, 128.5, 122.4, 108.4, 96.0, 83.0, 72.6, 68.4, 59.6, 55.5, 47.5, 41.9,
25.9, 25.8, 19.0, 2.5, 4.1; FTIR (neat film), cm1 2951 (w), 2930
(w), 1719 (s), 1674 (m), 1510 (s), 1175 (m), 1152 (m), 1038 (s), 934 (s),
829 (s), 735 (s); HRMSeESI (m/z): [MþH]þ calcd for C29H41N2O7Si,
557.2678; found, 557.2690.
4.2.11. b-Methoxymethoxymethyl trimethylsilyl enol ether 11. A so-
lution of n-butyllithium in hexanes (2.5 M, 374 mL, 0.936 mmol,
2.1 equiv) was added to a solution of tri-n-butyl[(methox-
ymethoxy)methyl]stannane19 (326 mg, 0.893 mmol, 2.0 equiv) in
tetrahydrofuran (4.0 mL) at 78 C. The resulting solution was
stirred at this temperature for 15 min, at which point hexame-
thylphosphoramide (313 mL, 1.78 mmol, 4.0 equiv) was added
dropwise. After stirring at 78 C for a further 1 min, a solution of
the AB enone 1 (215 mg, 0.446 mmol, 1 equiv) in tetrahydrofuran
(1.0 mL) was added to the reaction solution dropwise via syringe.
The reaction mixture was stirred at 78 C for 30 min whereupon
chlorotrimethylsilane (170 mL, 1.34 mmol, 3.0 equiv) was added.
After stirring at 78 C for 30 min, aqueous potassium phosphate
buffer solution (pH 7.0, 0.2 M, 10 mL) was added to the reaction
solution. The resulting mixture was allowed to warm to 23 C, then
was extracted with ethyl acetate (320 mL). The organic extracts
were combined and the combined solution was dried over anhy-
drous sodium sulfate. The dried solutionwas filtered and the filtrate
was concentrated. The product was purified by flash-column
chromatography (10% ethyl acetate/hexanes), affording b-methox-
ymethoxymethyl trimethylsilyl enol ether 11 as a pale yellow solid
(156 mg, 55%). Rf¼0.43 (20% ethyl acetate/hexanes); 1H NMR
(500 MHz, CDCl3) d 7.49e7.46 (m, 2H), 7.36e7.30 (m, 3H), 5.36 (AB
quartet, 2H), 4.78 (d, 1H, J¼2.4 Hz), 4.67 (s, 2H), 3.82 (d, 1H,
J¼9.8 Hz), 3.54e3.45 (m, 2H), 3.38 (s, 3H), 2.71e2.66 (m, 1H), 2.42
(s, 6H), 2.30e2.22 (m, 2H), 2.01 (d, 1H, J¼13.7 Hz), 0.86 (s, 9H), 0.23
(s, 3H), 0.12 (s, 3H), 0.05 (s, 9H); 13C NMR (125 MHz, CDCl3)
d 189.6, 181.6, 167.4, 148.9, 135.1, 128.7, 128.5, 128.4, 108.3, 105.8,
96.5, 81.1, 73.0, 72.2, 61.0, 55.2, 46.1, 41.9, 32.4, 26.0, 20.1, 18.9, 0.5,
2.8, 3.6; HRMSeESI (m/z): [MþNa]þ calcd for C32H50N2O7Si2Na,
653.3049; found, 653.3056.
4.2.12. b-Methoxymethoxymethyl AB enone 10 (alternative prepa-
ration). Palladium (II) acetate (242 mg, 1.06 mmol, 1.05 equiv) was
added to a solution of b-methoxymethoxymethyl trimethylsilyl
enol ether 11 (635 mg, 1.01 mmol, 1 equiv) in anhydrous dimethyl
sulfoxide (8.0 mL) at 23 C. The resulting mixture was heated to
50 C. After stirring at this temperature for 14 ½ h, the reaction
mixture was allowed to cool to 23 C. The cooled suspension was
diluted with ethyl acetate (50 mL) and the whole was filtered
through a pad of Celite. Hexanes (50 mL) were added to the filtrate
and the resulting solution was washed sequentially with saturated
aqueous sodium bicarbonate solution (50 mL) and saturated
aqueous sodium chloride solution (50 mL). The aqueous phases
were combined and the combined solution was extracted with
ethyl acetate/hexanes (1:1, 100 mL). The organic extracts were
combined and the combined solution was dried over anhydrous
sodium sulfate. The dried solution was filtered and the filtrate was
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tography (17% ethyl acetate/hexanes), affording the b-methox-
ymethoxymethyl AB enone 10 as a pale yellow solid (290 mg, 52%).
4.2.13. C5a-Methylminocycline (17). A freshly prepared solution of
lithium diisopropylamide in tetrahydrofuran (1.0 M, 1.21 mL,
1.21 mmol, 3.0 equiv) was added dropwise via syringe to a solution
of phenyl ester 12 (449 mg, 1.21 mmol, 3.0 equiv) and TMEDA
(365 mL, 2.42 mmol, 6.0 equiv) in tetrahydrofuran (15 mL) at
78 C, forming a bright red solution. After stirring at 78 C for
40 min, a solution of the b-methyl-substituted AB enone 3 (200 mg,
0.403 mmol, 1 equiv) in tetrahydrofuran (3.0 mL) was added to the
reaction solution dropwise via syringe. The resulting mixture was
allowed to warm slowly to 10 C over 80 min, then was parti-
tioned between aqueous potassium phosphate buffer solution (pH
7.0, 0.2 M, 60 mL) and dichloromethane (60 mL). The phases were
separated and the aqueous phase was extracted with dichloro-
methane (240 mL). The organic extracts were combined and the
combined solution was dried over anhydrous sodium sulfate. The
dried solution was filtered and the filtrate was concentrated,
affording an orange-yellow oil. The product was purified by flash-
column chromatography (15% ethyl acetate/hexanes, grading to
20%), providing the MichaeleClaisen cyclization product 14 as
a yellow solid (249 mg, 80%). Rf¼0.28 (20% ethyl acetate/hexanes);
1H NMR (600 MHz, CDCl3) d 15.96 (s, 1H), 7.49 (d, 2H, J¼7.8 Hz),
7.39e7.33 (m, 3H), 7.26e7.24 (m, 1H), 7.04 (d, 1H, J¼8.5 Hz), 5.36 (s,
2H), 4.16 (d, 1H, J¼10.0 Hz), 3.20 (d, 1H, J¼16.1 Hz), 2.75 (d, 1H,
J¼16.1 Hz), 2.66 (s, 6H), 2.54e2.50 (m, 7H), 2.37 (d, 1H, J¼14.4 Hz),
2.16 (dd, 1H, J¼14.8, 4.5 Hz), 1.56 (s, 9H), 1.12 (s, 3H), 0.90 (s, 9H),
0.25 (s, 3H), 0.21 (s, 3H); 13C NMR (125 MHz, CDCl3) d 186.8, 185.6,
181.7, 178.3, 167.6, 152.3, 150.4, 145.4, 136.4, 135.1, 128.5, 128.4,
128.3, 124.2, 123.9, 122.3, 112.0, 108.1, 83.8, 81.7, 72.4, 60.7, 47.0,
44.2, 41.9, 40.6, 32.4, 32.1, 29.8, 27.7, 26.4, 19.2, 1.9, 2.3; FTIR
(neat film), 1759 (w), 1721 (m), 1613 (w), 1510 (m), 1456 (w), 1265
(m), 1152 (m), 737 (s) cm1; HRMSeESI (m/z): [MþH]þ calcd for
C42H55N3O9Si, 774.3780; found, 774.3796.
Concentrated aqueous hydrofluoric acid solution (48 wt %,
2.0 mL) was added to a solution of the MichaeleClaisen cyclization
product 14 (249 mg, 0.322 mmol,1 equiv) in acetonitrile (3.0 mL) in
a polypropylene reaction vessel at 23 C. The reaction solution was
stirred vigorously at 23 C for 17 h, then was poured into water
(100 mL) containing dipotassium hydrogenphosphate trihydrate
(20.0 g). The resulting mixture was extracted with ethyl acetate
(100 mL, then 250 mL). The organic extracts were combined and
the combined solution was dried over anhydrous sodium sulfate.
The dried solution was filtered and the filtrate was concentrated,
affording an orange-brown solid. Methanol (3.0 mL) and dioxane
(3.0 mL) were added to the crude product, forming an orange-
brown solution. Palladium black (13.7 mg, 0.129 mmol, 0.4 equiv)
was added in one portion at 23 C. An atmosphere of hydrogenwas
introduced by briefly evacuating the flask, then flushing with pure
hydrogen (1 atm). The reaction mixture was stirred at 23 C for 1 h,
then was filtered through a plug of Celite. The filtrate was con-
centrated, affording a brownish yellow solid. The product was pu-
rified by preparative HPLC on an Agilent Prep C18 column [10 mm,
25021.2 mm, UV detection at 350 nm, solvent A: 0.1% trifluoro-
acetic acid in water, solvent B: acetonitrile, 2 batches, injection
volume: 5.0 mL (4.0 mL 0.1% trifluoroacetic acid in water, 1.0 mL
acetonitrile), gradient elution with 5/40% B over 50 min, flow
rate: 7.5 mL/min]. Fractions eluting at 24e31 min were collected
and concentrated, affording C5a-methylminocycline tri-
fluoroacetate 17 as a yellow solid (188 mg, 100%, two steps). 1H
NMR (600 MHz, CD3OD, trifluoroacetate) d 7.90 (d, 1H, J¼9.4 Hz),
7.07 (d, 1H, J¼9.4 Hz), 4.13 (d, 1H, J¼1.0 Hz), 3.25 (s, 6H), 3.17 (d, 1H,
J¼15.8 Hz), 3.07e3.02 (m, 1H), 3.04 (s, 6H), 2.80 (d, 1H, J¼15.7 Hz),
2.05 (dd, 1H, J¼13.8, 2.9 Hz), 1.93 (dd, 1H, J¼14.1, 13.9 Hz), 1.26 (s,3H); HRMSeESI (m/z): [MþH]þ calcd for C24H29N3O7, 472.2078;
found, 472.2087.
4.2.14. MichaeleClaisen cyclization product 15. A freshly prepared
solution of lithium diisopropylamide (1.0 M, 7.86 mL, 7.86 mmol,
3.6 equiv) was added dropwise via syringe to a solution of phenyl
ester 13 (2.84 g, 7.86 mmol, 3.6 equiv) and TMEDA (2.27 mL,
15.1 mmol, 7.0 equiv) in tetrahydrofuran (60 mL) at 78 C, form-
ing a bright red solution. After stirring at 78 C for 40 min, a so-
lution of the b-methoxymethoxymethyl AB enone 10 (1.20 g,
2.16 mmol, 1 equiv) in tetrahydrofuran (15 mL) was added to the
reaction solution dropwise via syringe. The resulting mixture was
allowed to warm slowly to 10 C over 80 min, then was parti-
tioned between aqueous potassium phosphate buffer solution (pH
7.0, 0.2 M, 100 mL) and dichloromethane (100 mL). The phases
were separated and the aqueous phase was further extracted with
dichloromethane (275 mL). The organic extracts were combined
and the combined solution was dried over anhydrous sodium sul-
fate. The dried solution was filtered and the filtrate was concen-
trated, affording an orange-yellow oil. The product was purified by
flash-column chromatography (3.5% ethyl acetate/dichloro-
methane), providing the MichaeleClaisen cyclization product 15 as
a yellow solid (1.29 g, 72%). Rf¼0.31 (30% ethyl acetate/hexanes); 1H
NMR (500 MHz, CDCl3) d 16.77 (s, 1H), 7.51 (d, 4H, J¼8.0 Hz),
7.41e7.28 (m, 6H), 7.21 (d, 1H, J¼9.0 Hz), 6.90 (d, 1H, J¼9.0 Hz), 5.38
(s, 2H), 5.17 (AB quartet, 2H), 4.47 (d, 1H, J¼6.5 Hz), 4.34 (d, 1H,
J¼6.5 Hz), 4.15 (d, 1H, J¼9.5 Hz), 3.78 (d, 1H, J¼16.5 Hz), 3.38 (d, 1H,
J¼9.0 Hz), 3.27 (d, 1H, J¼9.5 Hz), 3.12 (s, 3H), 2.63 (s, 6H), 2.65e2.58
(m,1H), 2.51 (s, 6H), 2.51e2.41 (m, 2H), 2.32 (dd,1H, J¼14.5, 2.0 Hz),
0.93 (s, 9H), 0.29 (s, 3H), 0.20 (s, 3H); 13C NMR (125 MHz, CDCl3)
d 186.9, 184.6, 183.0, 181.6, 167.7, 154.7, 145.7, 136.8, 136.1, 135.1,
128.5, 128.4, 128.4, 128.3, 127.7, 127.0, 125.0, 120.7, 113.7, 108.1, 107.2,
96.1, 82.3, 72.9, 72.4, 71.4, 61.1, 54.6, 46.4, 44.4, 41.9, 35.8, 34.7, 28.4,
26.5, 19.3, 2.0, 2.1; FTIR (neat film), 2932 (w), 1721 (s), 1611 (w),
1510 (m), 1472 (m), 1452 (m), 1269 (w), 1148 (w), 1107 (w), 1040 (s),
1020 (s), 922 (w), 831 (s), 733 (s) cm1; HRMSeESI (m/z): [MþH]þ
calcd for C46H58N3O9Si, 824.3937; found, 824.3885.
4.2.15. C5a-Carbomethoxyminocycline (18). A freshly prepared so-
lution of lithium diisopropylamide in tetrahydrofuran (1.0 M,
0.416 mL, 0.416 mmol, 3.0 equiv) was added dropwise via syringe
to a solution of phenyl ester 12 (155 mg, 0.416 mmol, 3.0 equiv) and
TMEDA (126 mL, 0.832 mmol, 6.0 equiv) in tetrahydrofuran (6 mL)
at 78 C, forming a bright red solution. After stirring at 78 C for
40 min, a solution of the b-methyl ester-substituted AB enone 5
(75 mg, 0.139 mmol, 1 equiv) in tetrahydrofuran (1.5 mL) was
added to the reaction solution dropwise via syringe. The resulting
mixture was allowed to warm slowly to 10 C over 75 min, then
was partitioned between aqueous potassium phosphate buffer
solution (pH 7.0, 0.2 M, 25 mL) and dichloromethane (25 mL). The
phases were separated and the aqueous phase was further
extracted with dichloromethane (220 mL). The organic extracts
were combined and the combined solution was dried over anhy-
drous sodium sulfate. The dried solutionwas filtered and the filtrate
was concentrated, affording a yellow solid. The crude product was
purified first by flash-column chromatography (15% acetone/hex-
anes), then by preparative HPLC on an Agilent Prep C18 column
[10 mm, 25021.2 mm, UV detection at 350 nm, solvent A: water,
solvent B: methanol, injection volume: 6.0 mL (5.0 mL methanol,
1.0 mL water), gradient elution with 85/100% B over 40 min, flow
rate: 15 mL/min]. Fractions eluting at 25e28 min were collected
and concentrated, providing the MichaeleClaisen cyclization
product 16 as a yellow solid (26 mg, 23%). Rf¼0.34 (25% ethyl ace-
tate/hexanes); 1H NMR (500 MHz, CDCl3) d 15.97 (s,1H), 7.49 (d, 2H,
J¼7.3 Hz), 7.39e7.33 (m, 3H), 7.24 (d, 1H, J¼8.3 Hz), 7.03 (d, 1H,
J¼8.3 Hz), 5.37 (s, 2H), 4.11 (d, 1H, J¼9.3 Hz), 3.84 (d, 1H, J¼16.1 Hz),
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2.57e2.53 (m, 2H), 2.51 (s, 6H), 1.57 (s, 9H), 0.82 (s, 9H), 0.23 (s, 3H),
0.17 (s, 3H); 13C NMR (125 MHz, CDCl3) d 187.6, 186.2, 181.5, 176.3,
175.2, 167.6, 152.4, 150.0, 145.4, 135.0, 134.2, 128.5, 128.5, 128.3,
124.6, 124.4, 123.1, 108.0, 106.8, 83.8, 80.9, 72.5, 60.6, 52.4, 46.6,
44.2, 44.1, 41.9, 38.2, 27.7, 26.2, 19.1, 2.1, 2.9; FTIR (neat film),
1761 (w), 1722 (m), 1512 (m), 1234 (s), 1150 (s), 833 (m), 733 (s)
cm1; HRMSeESI (m/z): [MþH]þ calcd for C43H56N3O11Si,
818.3679; found, 818.3760.
Concentrated aqueous hydrofluoric acid solution (48 wt %,
0.8 mL) was added to a solution of the HPLC-purified product 16
from the cyclization step above (25.0 mg, 0.031 mmol, 1 equiv) in
acetonitrile (1.2 mL) in a polypropylene reaction vessel at 23 C. The
reaction solution was stirred vigorously at 23 C for 17 h, then was
poured into water (30 mL) containing dipotassium hydro-
genphosphate trihydrate (10.0 g). The resulting mixture was
extracted with ethyl acetate (30 mL, then 220 mL). The organic
extracts were combined and the combined solution was dried over
anhydrous sodium sulfate. The dried solution was filtered and the
filtrate was concentrated, affording an orange solid. Palladium
black (4.9 mg, 0.046 mmol, 1.5 equiv) was added in one portion to
a solution of the crude product in methanol (1.5 mL) and dioxane
(1.5 mL) at 23 C. An atmosphere of hydrogen was introduced by
briefly evacuating the flask, then flushing with pure hydrogen
(1 atm). The reaction mixture was stirred at 23 C for 30 min, then
was filtered through a plug of Celite. The filtrate was concentrated,
affording a yellow solid. The product was purified by preparative
HPLC on an Agilent Prep C18 column [10 mm, 25021.2 mm, UV
detection at 350 nm, solvent A: 0.1% trifluoroacetic acid in water,
solvent B: acetonitrile, injection volume: 5.0 mL (4.0 mL 0.1% tri-
fluoroacetic acid inwater, 1.0 mL acetonitrile), gradient elutionwith
5/40% B over 50 min, flow rate: 7.5 mL/min]. Fractions eluting at
27e32 min were collected and concentrated, affording C5a-
carbomethoxyminocycline trifluoroacetate 18 as a yellow solid
(17.1 mg, 89%). 1H NMR (600 MHz, CD3OD) d 7.81 (d, 1H, J¼9.2 Hz),
7.03 (d, 1H, J¼9.2 Hz), 4.14 (s, 1H), 3.66 (d, 1H, J¼15.7 Hz), 3.61 (s,
3H), 3.14 (s, 6H), 2.97 (s, 6H), 2.87e2.83 (m, 2H), 2.53 (dd, 1H,
J¼14.3, 2.6 Hz), 2.04 (dd, 1H, J¼14.2, 14.1 Hz); HRMSeESI (m/z):
[MþH]þ calcd for C26H30N3O9, 516.1977; found, 516.2011.
4.2.16. Substituted neopentyl alcohol 19. Perchloric acid (CAU-
TION!)21 (13.0 mL, 70% solution) was added dropwise over 5 min to
a solution of the MichaeleClaisen cyclization product 15 (1.04 g,
1.26 mmol, 1 equiv) in tetrahydrofuran (130 mL) at 23 C. After
stirring at this temperature for 10 min, the reaction solution was
slowly and carefully poured into ice-cold saturated aqueous sodium
bicarbonate solution (300 mL). The resulting mixturewas extracted
with dichloromethane (2250 mL, then 50 mL). The organic ex-
tracts were combined and the combined solution was dried over
anhydrous sodium sulfate. The dried solution was filtered and the
filtrate was concentrated, providing an orange-yellow oil. The
product was purified by flash-column chromatography (55% ethyl
acetate/hexanes, grading to 75% ethyl acetate/hexanes), affording
the substituted neopentyl alcohol 19 as a yellow solid (720 mg,
73%). Rf¼0.26 (65% ethyl acetate/hexanes); 1H NMR (500 MHz,
CDCl3) d 16.76 (s, 1H), 7.53e7.49 (m, 4H), 7.41e7.28 (m, 6H), 7.22 (d,
1H, J¼9.0 Hz), 6.90 (d, 1H, J¼9.0 Hz), 5.38 (s, 2H), 5.17 (AB quartet,
2H), 4.11 (d, 1H, J¼9.5 Hz), 3.66 (d, 1H, J¼16.0 Hz), 3.48 (d, 1H,
J¼11.0 Hz), 3.32 (d, 1H, J¼11.0 Hz), 2.64 (s, 6H), 2.68e2.59 (m, 1H),
2.56e2.48 (m, 1H), 2.51 (s, 6H), 2.38 (dd, 1H, J¼14.5, 4.5 Hz), 2.23
(br d, 1H, J¼14.0 Hz), 0.92 (s, 9H), 0.25 (s, 3H), 0.18 (s, 3H); 13C NMR
(125 MHz, CDCl3) d 186.7, 184.7, 182.7, 181.4, 167.7, 154.9, 145.7,
136.8, 135.9, 135.1, 128.5, 128.5, 128.5, 128.3, 127.8, 126.9, 125.3,
120.7, 113.7, 108.2, 107.3, 82.3, 72.4, 71.4, 68.2, 61.3, 46.2, 44.7, 42.0,
36.8, 34.5, 28.2, 26.5, 19.3, 1.8, 2.0; FTIR (neat film), 2938 (w),
1719 (m), 1609 (w), 1510 (s), 1452 (s), 1265 (m), 1020 (m), 829 (s),733 (s) cm1; HRMSeESI (m/z): [MþH]þ calcd for C44H54N3O8Si,
780.3675; found,780.3654.
4.2.17. C5aeC11a-Bridged cyclopropane tetracycline precursor
20. 4A molecular sieves (2.4 g, small chunks) were added to a so-
lution of the substituted neopentyl alcohol 19 (720 mg,
0.923 mmol, 1 equiv) in dichloromethane (72 mL) and pyridine
(7.2 mL) at 23 C. The resulting mixture was stirred at 23 C for 1 h,
thenwas cooled to 0 C. A solution of phosgene in toluene (20 wt %,
537 mL, 1.02 mmol, 1.1 equiv) was added dropwise to the cooled
mixture. The resulting solution was stirred at 0 C for 1 h, where-
upon aqueous potassium phosphate buffer solution (pH 7.0, 0.2 M,
20 mL) was added. The resulting mixture was allowed to warm to
23 C, then was filtered to remove the molecular sieves. Dichloro-
methane (60 mL) and aqueous potassium phosphate buffer solu-
tion (pH 7.0, 0.2 M, 60 mL) were added and the phases were
separated. The aqueous phase was further extracted with
dichloromethane (260 mL). The organic extracts were combined
and the combined solution was dried over anhydrous sodium sul-
fate. The dried solution was filtered and the filtrate was concen-
trated, providing an orange-yellow oil. The product was purified by
flash-column chromatography (20% ethyl acetate/hexanes, grading
to 30% ethyl acetate/hexanes), affording the C5aeC11a-bridged
cyclopropane tetracycline precursor 20 as a white solid (572 mg,
81%). Rf¼0.25 (30% ethyl acetate/hexanes); 1H NMR (500 MHz,
CDCl3) d 7.52 (d, 2H, J¼7.3 Hz), 7.44e7.24 (m, 8H), 7.13 (d, 1H,
J¼9.0 Hz), 6.86 (d, 1H, J¼9.0 Hz), 5.35 (s, 2H), 5.05 (AB quartet, 2H),
4.01 (d, 1H, J¼10.5 Hz), 3.85 (d, 1H, J¼17.4 Hz), 2.77 (d, 1H,
J¼17.4 Hz), 2.68e2.57 (m, 3H), 2.62 (s, 6H), 2.49 (s, 6H), 2.25 (d, 1H,
J¼5.0 Hz), 1.71 (d, 1H, J¼5.0 Hz), 0.89 (s. 9H), 0.28, (s, 3H), 0.12 (s,
3H); 13C NMR (125 MHz, CDCl3) d 194.4, 191.8, 185.3, 180.9, 167.6,
152.6, 144.8, 136.7, 135.0, 132.2, 128.6, 128.5, 128.5, 128.4, 127.6,
127.1, 123.3, 123.2, 113.5, 107.9, 84.0, 72.6, 71.2, 58.8, 49.0, 44.8, 43.1,
41.8, 32.1, 31.1, 30.9, 26.6, 26.3, 19.5, 2.0, 2.6; FTIR (neat film),
2938 (w), 1728 (s), 1711 (m), 1670 (w), 1510 (m), 1474 (m), 1452 (m),
1362 (w), 1258 (m), 916 (m), 827 (s), 733 (s) cm1; HRMSeESI (m/
z): [MþH]þ calcd for C44H52N3O7Si, 762.3569; found,762.3569.
4.2.18. C5a-Pyrrolidinomethylminocycline (22). Anhydrous magne-
sium bromide (8.2 mg, 0.045 mmol, 2.0 equiv) was added to a so-
lution of the C5aeC11a-bridged cyclopropane 20 (17.0 mg,
0.022 mmol, 1 equiv) and pyrrolidine (18 mL, 0.223 mmol, 10 equiv)
in tetrahydrofuran (0.5 mL) at 23 C. The reaction mixture was
stirred at 23 C for 16 h, then was partitioned between dichloro-
methane and saturated aqueous sodium bicarbonate solution
(10 mL each). The phases were separated and the aqueous phase
was extracted with dichloromethane (10 mL). The organic extracts
were combined and the combined solution was dried over anhy-
drous sodium sulfate. The dried solutionwas filtered and the filtrate
was concentrated. The crude ring-opened product (21) was dis-
solved in acetonitrile (1.2 mL). The resulting solution was trans-
ferred to a polypropylene reaction vessel and concentrated aqueous
hydrofluoric acid solution (48 wt %, 0.8 mL) was added. The re-
action mixture was stirred vigorously at 23 C for 20 h, then was
poured into water (30 mL) containing dipotassium hydro-
genphosphate (8.0 g). The resulting mixture was extracted with
ethyl acetate (340 mL). The organic extracts were combined and
the combined solution was dried over anhydrous sodium sulfate.
The dried solution was filtered and the filtrate was concentrated.
Palladium black (5.0 mg, 0.047 mmol, 2.8 equiv) was added in one
portion to a solution of the crude product in methanol (1.0 mL) and
dioxane (1.0 mL) at 23 C. An atmosphere of hydrogen was in-
troduced by briefly evacuating the flask, then flushing with pure
hydrogen (1 atm). The reaction mixture was stirred at 23 C for 1
¼ h, then was filtered through a plug of Celite. The filtrate was
concentrated. The product was purified by preparative HPLC on an
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350 nm, solvent A: 0.1% trifluoroacetic acid in water, solvent B:
acetonitrile, injection volume: 5.0 mL (4.0 mL 0.1% trifluoroacetic
acid in water, 1.0 mL acetonitrile), gradient elution with 5/35% B
over 50 min, flow rate: 7.5 mL/min]. Fractions eluting at 39e43 min
were collected and concentrated, affording C5a-pyrrolidinomethyl-
minocycline bistrifluoroacetate 22 as a yellow solid (12.5 mg, 74%,
three steps). 1H NMR (600 MHz, CD3OD, bistrifluoroacetate) d 7.55
(d, 1H, J¼9.0 Hz), 6.95 (d, 1H, J¼9.0 Hz), 4.05 (s, 1H), 3.84 (br s, 1H),
3.75e3.71 (br s, 1H), 3.73 (d, 1H, J¼14.4 Hz), 3.62 (d, 1H, J¼16.8 Hz),
3.20 (d, 1H, J¼13.2 Hz), 3.14 (d, 1H, J¼15.0 Hz), 3.13e3.03 (br s, 1H),
3.10 (s, 6H), 2.70 (s, 6H), 2.67 (d,1H, J¼16.8 Hz), 2.59 (dd,1H, J¼15.0,
3.0 Hz), 2.50 (br s, 1H), 2.02e1.90 (m, 5H); HRMSeESI (m/z):
[MþH]þ calcd for C28H37N4O7, 541.2657; found, 541.2684.
4.2.19. C5a-Piperidinylmethylminocycline (23). Anhydrous magne-
sium bromide (8.2 mg, 0.045 mmol, 2.0 equiv) was added to a so-
lution of the C5aeC11a-bridged cyclopropane 20 (17.0 mg,
0.022 mmol, 1 equiv) and piperidine (22 mL, 0.223 mmol, 10 equiv)
in tetrahydrofuran (0.5 mL) at 23 C. The reaction mixture was
stirred at 23 C for 21 h, then was heated to 45 C. After stirring at
this temperature for 14 h, the reaction mixture was allowed to cool
to 23 C. The cooled mixture was partitioned between dichloro-
methane (15 mL) and saturated aqueous sodium bicarbonate so-
lution (10 mL). The phases were separated and the aqueous phase
was extracted with dichloromethane (10 mL). The organic extracts
were combined and the combined solution was dried over anhy-
drous sodium sulfate. The dried solutionwas filtered and the filtrate
was concentrated. The crude ring-opened product was dissolved in
acetonitrile (1.2 mL). The resulting solution was transferred to
a polypropylene reaction vessel and concentrated aqueous hydro-
fluoric acid solution (48 wt %, 0.8 mL) was added. The reaction
mixture was stirred vigorously at 23 C for 13 h, then was poured
into water (30 mL) containing dipotassium hydrogenphosphate
(8.0 g). The resulting mixture was extracted with ethyl acetate
(340 mL). The organic extracts were combined and the combined
solution was dried over anhydrous sodium sulfate. The dried so-
lution was filtered and the filtrate was concentrated. Palladium
black (5.0 mg, 0.047 mmol, 2.8 equiv) was added in one portion to
a solution of the crude product in methanol (1.0 mL) and dioxane
(1.0 mL) at 23 C. An atmosphere of hydrogen was introduced by
briefly evacuating the flask, then flushing with pure hydrogen
(1 atm). The reaction mixture was stirred at 23 C for 1 ½ h, then
was filtered through a plug of Celite. The filtrate was concentrated.
The product was purified by preparative HPLC on an Agilent Prep
C18 column [10 mm, 25021.2 mm, UV detection at 350 nm, solvent
A: 0.1% trifluoroacetic acid in water, solvent B: acetonitrile, in-
jection volume: 5.0 mL (4.0 mL 0.1% trifluoroacetic acid in water,
1.0 mL acetonitrile), gradient elution with 5/35% B over 50 min,
flow rate: 7.5 mL/min]. Fractions eluting at 40e44 min were col-
lected and concentrated, affording C5a-piperidinylmethylmino-
cycline bistrifluoroacetate 23 as a yellow solid (12.0 mg, 70%,
three steps). 1H NMR (600 MHz, CD3OD, bistrifluoroacetate) d 7.56
(d, 1H, J¼9.0 Hz), 6.96 (d, 1H, J¼9.0 Hz), 4.10 (d, 1H, J¼2.4 Hz), 3.66
(d, 1H, J¼16.8 Hz), 3.46 (d, 1H, J¼14.4 Hz), 3.40e3.35 (br m, 1H),
3.27e3.23 (m, 1H), 3.23e3.18 (m, 1H), 3.10 (s, 6H), 3.10e3.00 (m,
2H), 2.71 (s, 6H), 2.71e2.62 (m, 2H), 2.59 (dd, 1H, J¼15.0, 3.0 Hz),
2.02 (dd, 1H, J¼15.1, 12.7 Hz), 1.95e1.88 (br m, 1H), 1.85e1.78 (br m,
2H), 1.72e1.61 (br m, 2H), 1.43e1.36 (br m, 1H); HRMSeESI (m/z):
[MþH]þ calcd for C29H39N4O7, 555.2813; found, 555.2788.
4.2.20. C5a-Morpholinomethylminocycline (24). Anhydrous mag-
nesium bromide (6.3 mg, 0.034 mmol, 2.0 equiv) was added to
a solution of the C5aeC11a-bridged cyclopropane 20 (13.0 mg,
0.017 mmol, 1 equiv) and morpholine (15 mL, 0.17 mmol, 10 equiv)
in tetrahydrofuran (0.5 mL) at 23 C. The reaction flask was sealedand the reaction mixture was heated to 55 C. After stirring at 55 C
for 14 h, the reaction mixture was allowed to cool to 23 C. The
cooled mixture was partitioned between dichloromethane and
saturated aqueous sodium bicarbonate solution (10 mL each). The
phases were separated and the aqueous phase was further
extractedwith dichloromethane (10 mL). The organic extracts were
combined and the combined solution was dried over anhydrous
sodium sulfate. The dried solution was filtered and the filtrate was
concentrated. The crude ring-opened product was dissolved in
acetonitrile (1.2 mL). The resulting solution was transferred to
a polypropylene reaction vessel and concentrated aqueous hydro-
fluoric acid solution (48 wt %, 0.8 mL) was added. The reaction
mixture was stirred vigorously at 23 C for 16 ½ h, thenwas poured
into water (30 mL) containing dipotassium hydrogenphosphate
(8.0 g). The resulting mixture was extracted with ethyl acetate
(340 mL). The organic extracts were combined and the combined
solution was dried over anhydrous sodium sulfate. The dried so-
lution was filtered and the filtrate was concentrated. Palladium
black (5.0 mg, 0.047 mmol, 2.8 equiv) was added in one portion to
a solution of the crude product in methanol (1.0 mL) and dioxane
(1.0 mL) at 23 C. An atmosphere of hydrogen was introduced by
briefly evacuating the flask, then flushing with pure hydrogen
(1 atm). The reaction mixture was stirred at 23 C for 1 3/4 h, then
was filtered through a plug of Celite. The filtrate was concentrated.
The product was purified by preparative HPLC on an Agilent Prep
C18 column [10 mm, 25021.2 mm, UV detection at 350 nm, solvent
A: 0.1% trifluoroacetic acid in water, solvent B: acetonitrile, in-
jection volume: 5.0 mL (4.0 mL 0.1% trifluoroacetic acid in water,
1.0 mL acetonitrile), gradient elution with 5/25% B over 50 min,
then 25/100% B over 20 min, flow rate: 7.5 mL/min]. Fractions
eluting at 49e52 min were collected and concentrated, affording
C5a-morpholinomethylminocycline bistrifluoroacetate 24 as an
orange-yellow solid (7.5 mg, 56%, three steps). 1H NMR (600 MHz,
CD3OD, bistrifluoroacetate) d 7.56 (d, 1H, J¼9.0 Hz), 6.95 (d, 1H,
J¼9.0 Hz), 4.04 (s, 1H), 3.77e3.69 (m, 4H), 3.53 (d, 1H, J¼16.8 Hz),
3.24 (d, 1H, J¼13.2 Hz), 3.18e3.14 (m, 1H), 3.08 (s, 6H), 2.99e2.94
(m, 2H), 2.88 (d,1H, J¼15.0 Hz), 2.81e2.72 (m, 2H), 2.74 (s, 6H), 2.62
(d, 1H, J¼16.8 Hz), 2.53 (br d, 1H, J¼14.4 Hz), 1.92 (dd, 1H, J¼14.2,
14.0 Hz); HRMSeESI (m/z): [MþH]þ calcd for C28H37N4O8,
557.2606; found, 557.2611.
4.2.21. C5a-Diethylaminomethylminocycline (25). Anhydrous mag-
nesium bromide (7.2 mg, 0.039 mmol, 2.0 equiv) was added to
a solution of the C5aeC11a-bridged cyclopropane 20 (15.0 mg,
0.020 mmol, 1 equiv) and diethylamine (102 mL, 0.987 mmol,
50 equiv) in tetrahydrofuran (0.5 mL) at 23 C. The reaction flask
was sealed and the reaction mixture was heated to 45 C. After
stirring at this temperature for 20 h, the reaction mixture was
allowed to cool to room temperature. The reaction flask was
opened briefly and a second portion of diethylamine (204 mL,
1.97 mmol, 100 equiv) was added. The flask was re-sealed and the
reaction mixture was heated to 45 C. After stirring at this tem-
perature for a further 55 h, the reaction mixture was allowed to
cool to 23 C. The cooled mixture was partitioned between
dichloromethane and saturated aqueous sodium bicarbonate so-
lution (10 mL each). The phases were separated and the aqueous
phase was extracted with dichloromethane (10 mL). The organic
extracts were combined and the combined solution was dried over
anhydrous sodium sulfate. The dried solution was filtered and the
filtrate was concentrated. The crude ring-opened product was
dissolved in acetonitrile (1.2 mL). The resulting solution was
transferred to a polypropylene reaction vessel and concentrated
aqueous hydrofluoric acid solution (48 wt %, 0.8 mL) was added.
The reaction mixture was stirred vigorously at 23 C for 10 ½ h,
then was poured into water (30 mL) containing dipotassium
hydrogenphosphate (8.0 g). The resulting mixture was extracted
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and the combined solution was dried over anhydrous sodium
sulfate. The dried solution was filtered and the filtrate was con-
centrated. Palladium black (5.0 mg, 0.047 mmol, 2.8 equiv) was
added in one portion to a solution of the crude product in
methanol (1.0 mL) and dioxane (1.0 mL) at 23 C. An atmosphere
of hydrogen was introduced by briefly evacuating the flask, then
flushing with pure hydrogen (1 atm). The reaction mixture was
stirred at 23 C for 1 3/4 h, then was filtered through a plug of
Celite. The filtrate was concentrated. The product was purified by
preparative HPLC on an Agilent Prep C18 column [10 mm,
25021.2 mm, UV detection at 350 nm, solvent A: 0.1% trifluoro-
acetic acid in water, solvent B: acetonitrile, injection volume:
5.0 mL (4.0 mL 0.1% trifluoroacetic acid in water, 1.0 mL acetoni-
trile), gradient elution with 5/40% B over 50 min, flow rate:
7.5 mL/min]. Fractions eluting at 36e39 min were collected and
concentrated, affording C5a-diethylaminomethylminocycline bis-
trifluoroacetate 25 as a yellow solid (12.0 mg, 79%, three steps). 1H
NMR (600 MHz, CD3OD, bistrifluoroacetate) d 7.54 (d, 1H,
J¼9.0 Hz), 6.95 (d, 1H, J¼9.0 Hz), 4.10 (d, 1H, J¼3.0 Hz), 3.61 (d, 1H,
J¼16.8 Hz), 3.42 (d, 1H, J¼15.0 Hz), 3.25e3.20 (m, 2H), 3.16e3.02
(br m, 3H), 3.10 (s, 6H), 2.93 (br s, 1H), 2.73e2.69 (m, 1H), 2.70 (s,
6H), 2.52 (dd, 1H, J¼15.0, 3.0 Hz), 2.07 (dd, 1H, J¼14.1, 13.3 Hz),
1.28 (br s, 3H), 1.04 (br s, 3H); HRMSeESI (m/z): [MþH]þ calcd for
C28H39N4O7, 543.2813; found, 543.2821.
4.2.22. C5a-N-Imidazolylmethylminocycline (26). Anhydrous mag-
nesium bromide (7.2 mg, 0.039 mmol, 3.0 equiv) was added to
a solution of the C5aeC11a-bridged cyclopropane 20 (10.0 mg,
0.013 mmol, 1 equiv) and imidazole (6.2 mg, 0.091 mmol,
7.0 equiv) in tetrahydrofuran (0.5 mL) at 23 C. The reaction flask
was sealed and the reaction mixture was heated to 60 C. After
stirring at this temperature for 60 h, the reaction mixture was
allowed to cool to 23 C. The cooled mixture was partitioned be-
tween dichloromethane and saturated aqueous sodium bi-
carbonate solution (15 mL each). The phases were separated and
the aqueous phase was extracted with dichloromethane (15 mL).
The organic extracts were combined and the combined solution
was dried over anhydrous sodium sulfate. The dried solution was
filtered and the filtrate was concentrated. The crude ring-opened
product was dissolved in acetonitrile (1.2 mL). The resulting so-
lution was transferred to a polypropylene reaction vessel and
concentrated aqueous hydrofluoric acid solution (48 wt %, 0.8 mL)
was added. The reaction mixture was stirred vigorously at 23 C
for 18 h, then was poured into water (30 mL) containing dipotas-
sium hydrogenphosphate (8.0 g). The resulting mixture was
extracted with ethyl acetate (340 mL). The organic extracts were
combined and the combined solution was dried over anhydrous
sodium sulfate. The dried solution was filtered and the filtrate was
concentrated. Palladium black (5.0 mg, 0.047 mmol, 3.6 equiv) was
added in one portion to a solution of the crude product in
methanol (1.0 mL) and dioxane (1.0 mL) at 23 C. An atmosphere
of hydrogen was introduced by briefly evacuating the flask, then
flushing with pure hydrogen (1 atm). The reaction mixture was
stirred at 23 C for 1 ¼ h, then was filtered through a plug of
Celite. The filtrate was concentrated. The product was purified by
preparative HPLC on an Agilent Prep C18 column [10 mm,
25021.2 mm, UV detection at 350 nm, solvent A: 0.1% trifluoro-
acetic acid in water, solvent B: acetonitrile, injection volume:
5.0 mL (4.0 mL 0.1% trifluoroacetic acid in water, 1.0 mL acetoni-
trile), gradient elution with 5/40% B over 50 min, flow rate:
7.5 mL/min]. Fractions eluting at 25e27 min were collected and
concentrated, affording C5a-imidazolylmethylminocycline bistri-
fluoroacetate 26 as a yellow solid (7.3 mg, 73%, three steps). 1H
NMR (600 MHz, CD3OD, bistrifluoroacetate) d 8.42 (t, 1H,
J¼1.3 Hz), 7.51 (d, 1H, J¼9.0 Hz), 7.40 (dd, 1H, J¼1.8, 1.5 Hz), 7.23(dd, 1H, J¼1.8, 1.6 Hz), 6.86 (d, 1H, J¼9.0 Hz), 4.48 (AB quartet, 2H),
4.13 (s, 1H), 3.42 (d, 1H, J¼16.8 Hz), 3.25 (dd, 1H, J¼13.8, 1.2 Hz),
3.11 (s, 6H), 2.73 (s, 6H), 2.69 (d, 1H, J¼16.2 Hz), 2.14 (dd, 1H,
J¼15.0, 3.0 Hz), 1.98 (dd, 1H, J¼14.5, 14.2 Hz); HRMSeESI (m/z):
[MþH]þ calcd for C27H32N5O7, 538.2296; found, 538.2285.
4.2.23. C5a-Cyclopropylaminomethylminocycline (27). Anhydrous
magnesium bromide (8.2 mg, 0.045 mmol, 2.0 equiv) was added to
a solution of the C5aeC11a-bridged cyclopropane 20 (17.0 mg,
0.022 mmol, 1 equiv) and cyclopropylamine (15 mL, 0.223 mmol,
10 equiv) in tetrahydrofuran (0.5 mL) at 23 C. The reaction mix-
ture was stirred at 23 C for 16 h, then was heated to 40 C. After
stirring at this temperature for 22 h, the reaction mixture was
allowed to cool to room temperature. The reaction flask was
opened briefly and a second portion of cyclopropylamine (15 mL,
0.223 mmol, 10 equiv) was added. The flask was sealed and the
reaction mixture was heated to 40 C. After stirring at this tem-
perature for a further 13 h, the reaction mixture was allowed to
cool to 23 C. The cooled mixture was partitioned between
dichloromethane (15 mL) and saturated aqueous sodium bi-
carbonate solution (10 mL). The phases were separated and the
aqueous phase was extracted with dichloromethane (10 mL). The
organic extracts were combined and the combined solution was
dried over anhydrous sodium sulfate. The dried solution was fil-
tered and the filtrate was concentrated. The crude ring-opened
product was dissolved in acetonitrile (1.2 mL). The resulting so-
lution was transferred to a polypropylene reaction vessel and
concentrated aqueous hydrofluoric acid solution (48 wt %, 0.8 mL)
was added. The reaction mixture was stirred vigorously at 23 C
for 12 h, then was poured into water (30 mL) containing dipotas-
sium hydrogenphosphate (8.0 g). The resulting mixture was
extracted with ethyl acetate (340 mL). The organic extracts were
combined and the combined solution was dried over anhydrous
sodium sulfate. The dried solution was filtered and the filtrate was
concentrated. Palladium black (5.0 mg, 0.047 mmol, 2.8 equiv) was
added in one portion to a solution of the crude product in
methanol (1.0 mL) and dioxane (1.0 mL) at 23 C. An atmosphere
of hydrogen was introduced by briefly evacuating the flask, then
flushing with pure hydrogen (1 atm). The reaction mixture was
stirred at 23 C for 3 ½ h, then was filtered through a plug of
Celite. The filtrate was concentrated. The product was purified by
preparative HPLC on an Agilent Prep C18 column [10 mm,
25021.2 mm, UV detection at 350 nm, solvent A: 0.1% trifluoro-
acetic acid in water, solvent B: acetonitrile, injection volume:
5.0 mL (4.0 mL 0.1% trifluoroacetic acid in water, 1.0 mL acetoni-
trile), gradient elution with 5/35% B over 50 min, flow rate:
7.5 mL/min]. Fractions eluting at 35e36 min were collected and
concentrated, affording C5a-cyclopropylaminomethylminocycline
bistrifluoroacetate 27 as a yellow solid (3.0 mg, 18%, three
steps).27 1H NMR (600 MHz, CD3OD, bistrifluoroacetate) d 7.58 (d,
1H, J¼9.0 Hz), 6.96 (d, 1H, J¼9.0 Hz), 4.00 (d, 1H, J¼2.4 Hz), 3.60 (d,
1H, J¼14.4 Hz), 3.55 (d, 1H, J¼16.8 Hz), 3.19e3.10 (m, 1H), 3.13 (s,
6H), 3.03 (d, 1H, J¼14.4 Hz), 2.76 (s, 6H), 2.76e2.70 (m, 1H),
2.62e2.58 (m, 1H), 2.25 (dd, 1H, J¼14.8, 2.8 Hz), 1.98 (dd, 1H,
J¼14.2, 13.8 Hz), 0.89e0.82 (m, 1H), 0.77e0.69 (m, 3H); HRMSeESI
(m/z): [MþH]þ calcd for C27H35N4O7, 527.2500; found, 527.2502.
4.2.24. C5a-Methoxymethylminocycline (28). Anhydrous magne-
sium bromide (9.1 mg, 0.049 mmol, 2.5 equiv) was added to a so-
lution of the C5aeC11a-bridged cyclopropane 20 (15.0 mg,
0.020 mmol, 1 equiv) in methanol (1.5 mL) at 23 C. The reaction
flask was sealed and the reactionmixturewas heated to 65 C. After
stirring at 65 C for 24 h, the reaction mixture was allowed to cool
to 23 C. The cooled mixture was partitioned between aqueous
potassium phosphate buffer solution (pH 7.0, 0.2 M, 10 mL) and
dichloromethane (10 mL). The phases were separated and the
P.M. Wright, A.G. Myers / Tetrahedron 67 (2011) 9853e9869 9867aqueous phase was extracted with dichloromethane (10 mL). The
organic extracts were combined and the combined solution was
dried over anhydrous sodium sulfate. The dried solution was fil-
tered and the filtrate was concentrated. The crude ring-opened
product was dissolved in acetonitrile (1.2 mL). The resulting solu-
tion was transferred to a polypropylene reaction vessel and con-
centrated aqueous hydrofluoric acid solution (48 wt %, 0.8 mL) was
added. The reactionmixturewas stirred vigorously at 23 C for 15 h,
then was poured into water (30 mL) containing dipotassium
hydrogenphosphate trihydrate (10.0 g). The resulting mixture was
extracted with ethyl acetate (330 mL). The organic extracts were
combined and the combined solution was dried over anhydrous
sodium sulfate. The dried solution was filtered and the filtrate was
concentrated. Palladium black (6.0 mg, 0.057 mmol, 2.8 equiv) was
added in one portion to a solution of the crude product in methanol
(1.0 mL) and dioxane (1.0 mL) at 23 C. An atmosphere of hydrogen
was introduced by briefly evacuating the flask, then flushing with
pure hydrogen (1 atm). The reaction mixture was stirred at 23 C
for 2 ½ h, thenwas filtered through a plug of Celite. The filtrate was
concentrated. The product was purified by preparative HPLC on an
Agilent Prep C18 column [10 mm, 25021.2 mm, UV detection at
350 nm, solvent A: 0.1% trifluoroacetic acid in water, solvent B:
acetonitrile, injection volume: 7.0 mL (6.0 mL 0.1% trifluoroacetic
acid in water, 1.0 mL acetonitrile), gradient elution with 5/40% B
over 50 min, flow rate: 7.5 mL/min]. Fractions eluting at 29e33 min
were collected and concentrated, affording C5a-methoxymethy-
lminocycline trifluoroacetate 28 as a yellow solid (7.1 mg, 58%,
three steps). 1H NMR (600 MHz, CD3OD, hydrochloride) d 7.82 (d,
1H, J¼9.4 Hz), 7.05 (d, 1H, J¼9.2 Hz), 4.15 (s, 1H), 3.49 (d, 1H,
J¼10.3 Hz), 3.36 (d, 1H, J¼15.6 Hz), 3.25 (s, 3H), 3.14 (s, 6H), 3.12 (d,
1H, J¼10.3 Hz), 3.08e3.04 (m, 1H), 2.99 (s, 6H), 2.56 (d, 1H,
J¼15.6 Hz), 2.41 (dd, 1H, J¼14.1, 2.9 Hz), 1.69 (dd, 1H, J¼14.1,
13.9 Hz); HRMSeESI (m/z): [MþH]þ calcd for C25H32N3O8,
502.2184; found, 502.2186.
4.2.25. C5a-n-Butoxymethylminocycline (29). Anhydrous magne-
sium bromide (7.2 mg, 0.039 mmol, 2.0 equiv) was added to a so-
lution of the C5aeC11a-bridged cyclopropane 20 (15.0 mg,
0.020 mmol, 1 equiv) in n-butanol (1.0 mL) at 23 C. The resulting
mixture was heated to 75 C. After stirring at 75 C for 14 h, the
reaction mixture was allowed to cool to 23 C. The cooled mixture
was partitioned between aqueous potassium phosphate buffer
solution (pH 7.0, 0.2 M, 10 mL) and dichloromethane (10 mL). The
phases were separated and the aqueous phase was extracted with
dichloromethane (10 mL). The organic extracts were combined and
the combined solution was dried over anhydrous sodium sulfate.
The dried solution was filtered and the filtrate was concentrated.
The crude ring-opened product was dissolved in acetonitrile
(1.2 mL). The resulting solution was transferred to a polypropylene
reaction vessel and concentrated aqueous hydrofluoric acid solu-
tion (48 wt %, 0.8 mL) was added. The reaction mixture was stirred
vigorously at 23 C for 13 ½ h, then was poured into water (30 mL)
containing dipotassium hydrogenphosphate (8.0 g). The resulting
mixture was extracted with ethyl acetate (340 mL). The organic
extracts were combined and the combined solution was dried over
anhydrous sodium sulfate. The dried solution was filtered and the
filtrate was concentrated. Palladium black (5.0 mg, 0.047 mmol,
2.4 equiv) was added in one portion to a solution of the crude
product in methanol (1.0 mL) and dioxane (1.0 mL) at 23 C. An
atmosphere of hydrogen was introduced by briefly evacuating the
flask, then flushing with pure hydrogen (1 atm). The reaction
mixture was stirred at 23 C for 3 3/4 h, then was filtered through
a plug of Celite. The filtrate was concentrated. The product was
purified by preparative HPLC on an Agilent Prep C18 column
[10 mm, 25021.2 mm, UV detection at 350 nm, solvent A: 0.1%
trifluoroacetic acid in water, solvent B: acetonitrile, injectionvolume: 5.0 mL (4.0 mL 0.1% trifluoroacetic acid in water, 1.0 mL
acetonitrile), gradient elution with 5/40% B over 50 min, flow
rate: 7.5 mL/min]. Fractions eluting at 41e44 min were collected
and concentrated, affording C5a-n-butoxymethylminocycline tri-
fluoroacetate 29 as a yellow solid (7.3 mg, 56%, three steps). 1H NMR
(600 MHz, CD3OD, trifluoroacetate) d 7.81 (d, 1H, J¼9.0 Hz), 7.04 (d,
1H, J¼9.6 Hz), 4.16 (s, 1H), 3.50 (d, 1H, J¼10.2 Hz), 3.38e3.30 (m,
3H), 3.21 (d, 1H, J¼9.6 Hz), 3.13 (s, 6H), 3.11e3.06 (m, 1H), 2.98 (s,
6H), 2.58 (d, 1H, J¼15.6 Hz), 2.42 (dd, 1H, J¼13.8, 3.0 Hz), 1.71 (dd,
1H, J¼13.9, 13.8 Hz), 1.50e1.39 (m, 2H), 1.34e1.24 (m, 2H), 0.87 (t,
3H, J¼7.2 Hz); HRMSeESI (m/z): [MþH]þ calcd for C28H38N3O8,
544.2653; found, 544.2655.
4.2.26. C5a-Methoxyethoxymethylminocycline (30). Anhydrous
magnesium bromide (6.2 mg, 0.034 mmol, 2.0 equiv) was added to
a solution of the C5aeC11a-bridged cyclopropane 20 (13.0 mg,
0.017 mmol, 1 equiv) in 2-methoxyethanol (0.5 mL) at 23 C. The
resulting mixture was heated to 60 C. After stirring at 60 C for
26 h, the reaction mixture was allowed to cool to 23 C. The cooled
mixture was partitioned between aqueous potassium phosphate
buffer solution (pH 7.0, 0.2 M, 10 mL) and dichloromethane
(10 mL). The phases were separated and the aqueous phase was
further extracted with dichloromethane (10 mL). The organic ex-
tracts were combined and the combined solution was dried over
anhydrous sodium sulfate. The dried solution was filtered and the
filtrate was concentrated. The crude ring-opened product was
dissolved in acetonitrile (1.2 mL). The resulting solution was
transferred to a polypropylene reaction vessel and concentrated
aqueous hydrofluoric acid solution (48 wt %, 0.8 mL) was added.
The reaction mixture was stirred vigorously at 23 C for 10 ½ h,
then was poured into water (30 mL) containing dipotassium
hydrogenphosphate (8.0 g). The resulting mixture was extracted
with ethyl acetate (340 mL). The organic extracts were combined
and the combined solution was dried over anhydrous sodium
sulfate. The dried solution was filtered and the filtrate was con-
centrated. Palladium black (5.0 mg, 0.047 mmol, 2.8 equiv) was
added in one portion to a solution of the crude product in
methanol (1.0 mL) and dioxane (1.0 mL) at 23 C. An atmosphere
of hydrogen was introduced by briefly evacuating the flask, then
flushing with pure hydrogen (1 atm). The reaction mixture was
stirred at 23 C for 1 3/4 h, then was filtered through a plug of
Celite. The filtrate was concentrated. The product was purified by
preparative HPLC on an Agilent Prep C18 column [10 mm,
25021.2 mm, UV detection at 350 nm, solvent A: 0.1% trifluoro-
acetic acid in water, solvent B: acetonitrile, injection volume:
5.0 mL (4.0 mL 0.1% trifluoroacetic acid in water, 1.0 mL acetoni-
trile), gradient elution with 5/40% B over 50 min, flow rate:
7.5 mL/min]. Fractions eluting at 32e34 min were collected and
concentrated, affording C5a-methoxyethoxymethylminocycline
trifluoroacetate 30 as a yellow solid (5.8 mg, 52%, three steps).
1H NMR (600 MHz, CD3OD, trifluoroacetate) d 7.83 (d, 1 h,
J¼9.0 Hz), 7.05 (d, 1H, J¼9.0 Hz), 4.13 (s, 1H), 3.54e3.45 (m, 4H),
3.44e3.40 (m, 1H), 3.34 (d, 1H, J¼15.6 Hz), 3.27e3.25 (m, 1H), 3.26
(s, 3H), 3.18 (s, 6H), 3.11 (br d, 1H, J¼14.4 Hz), 2.99 (s, 6H), 2.61 (d,
1H, J¼16.2 Hz), 2.45 (dd, 1H, J¼14.4, 3.0 Hz), 1.71 (t, 1H, J¼14.4 Hz);
HRMSeESI (m/z): [MþH]þ calcd for C27H36N3O9, 546.2446; found,
546.2459.
4.2.27. Azido-substituted ring-opened product (31). Sodium azide
(50.0 mg, 0.763 mmol, 3.0 equiv) was added to a solution of the
C5aeC11a-bridged cyclopropane 20 (194 mg, 0.255 mmol, 1 equiv)
in dimethylformamide (7.5 mL) at 23 C. The resulting solutionwas
stirred at this temperature for 14 h, then was partitioned between
saturated aqueous sodium chloride solution and diethyl ether
(60 mL each). The phases were separated and the aqueous phase
was further extracted with diethyl ether (60 mL). The organic
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anhydrous sodium sulfate. The dried solution was filtered and the
filtrate was concentrated. The product was purified by flash-
column chromatography (12% ethyl acetate/hexanes), providing
the azido-substituted ring-opened product 31 as a yellow solid
(160 mg, 78%). Rf¼0.41 (30% ethyl acetate/hexanes); 1H NMR
(500 MHz, CDCl3) d 16.72 (s, 1H), 7.51 (br d, 4H, J¼8.0 Hz), 7.41e7.26
(m, 7H), 6.95 (d, 1H, 8.5 Hz), 5.38 (s, 2H), 5.18 (AB quartet, 2H), 4.11
(d, 1H, J¼10.5 Hz), 3.72 (d, 1H, J¼16.5 Hz), 3.30 (d, 1H, J¼11.5 Hz),
3.13 (d, 1H, J¼11.5 Hz), 2.65 (s, 6H), 2.65e2.45 (m, 2H), 2.51 (s, 6H),
2.35e2.25 (m, 2H), 0.92 (s, 9H), 0.27 (s, 3H), 0.19 (s, 3H); 13C NMR
(125 MHz, CDCl3) d 186.5, 184.0, 183.6, 181.5, 167.7, 154.9, 145.9,
136.7, 135.3, 135.0, 128.5, 128.5, 128.5, 128.4, 127.9, 127.0, 125.8,
120.2, 114.0, 108.3, 107.3, 82.3, 72.5, 71.5, 61.1, 59.1, 46.6, 44.6, 41.9,
36.4, 35.2, 28.3, 26.5, 19.3, -1.9, -2.1; FTIR (neat film), 2099 (s), 1721
(s), 1609 (m), 1510 (s), 1258 (m), 829 (s) cm1; HRMSeESI (m/z):
[MþH]þ calcd for C44H53N6O7Si, 805.3740; found, 805.3722.
4.2.28. C5a-Aminomethylminocycline (32)26,27. A solution of tri-
methylphospine in tetrahydrofuran (1.0 M, 398 mL, 0.398 mmol,
2.0 equiv) was added dropwise via syringe to a solution of the
azido-substituted ring-opened product 31 (160 mg, 0.199 mmol,
1 equiv) and 2-(tert-butoxycarbonyloxyimino)-2-phenylacetoni-
trile (98.0 mg, 0.398 mmol, 2.0 equiv) in tetrahydrofuran at
10 C. The reaction mixture was allowed to warm to 23 C over
15 min. After stirring at this temperature for 15 h, the product so-
lutionwas partitioned between dichloromethane and water (60 mL
each). The phases were separated and the organic phase was
washed sequentially with water (60 mL) and saturated aqueous
sodium chloride solution (260 mL). The organic solutionwas then
dried over anhydrous sodium sulfate. The dried solution was fil-
tered and the filtrate was concentrated. The product was purified
by flash-column chromatography (25% ethyl acetate/hexanes),
providing the desired tert-butyl carbamate as a yellow solid (90 mg,
51%). Methanol (2.5 mL) and dioxane (2.5 mL) were added to this
product, forming a yellow solution. Palladium black (25 mg,
0.235 mmol, 2.3 equiv) was added in one portion at 23 C. An at-
mosphere of hydrogen was introduced by briefly evacuating the
flask, then flushing with pure hydrogen (1 atm). The reaction
mixture was stirred at 23 C for 1 h, whereupon more palladium
black (25 mg) was added. The resulting mixturewas stirred at 23 C
for a further 2 h, then was filtered through a plug of Celite. The
filtrate was concentrated, providing an orange solid. Concentrated
aqueous hydrofluoric acid (48 wt %, 1.4 mL) was added to a solution
of the crude product in acetonitrile (2.0 mL) in a polypropylene
reaction vessel at 23 C. The reactionmixturewas stirred vigorously
at 23 C for 15 h. Excess hydrofluoric acid was quenched by the
careful addition of methoxytrimethylsilane (9.0 mL). The resulting
mixturewas concentrated. The product was purified by preparative
HPLC on an Agilent Prep C18 column [10 mm, 25021.2 mm, UV
detection at 350 nm, solvent A: 0.1% trifluoroacetic acid in water,
solvent B: acetonitrile, injection volume: 5.0 mL (4.0 mL 0.1% tri-
fluoroacetic acid inwater, 1.0 mL acetonitrile), gradient elutionwith
5/40% B over 50 min, flow rate: 7.5 mL/min]. Fractions eluting at
22e27 min were collected and concentrated, affording C5a-
aminomethylminocycline bistrifluoroacetate 32 as a yellow solid
(50 mg, 69%, two steps). 1H NMR (500 MHz, CD3OD, bistri-
fluoroacetate) d 7.88 (d, 1H, J¼9.0 Hz), 7.10 (d, 1H, J¼9.0 Hz), 4.09 (d,
1H, J¼2.5 Hz), 3.60 (d,1H, J¼17.0 Hz), 3.34 (d,1H, J¼14.5 Hz), 3.18 (s,
6H), 3.16 (s, 6H), 3.20e3.14 (m, 1H), 3.02 (d, 1H, J¼14.5 Hz), 2.95 (d,
1H, J¼17.0 Hz), 2.33 (dd, 1H, J¼15.0, 3.0 Hz), 1.96 (dd, 1H, J¼14.6,
13.7 Hz); HRMSeESI (m/z): [MþH]þ calcd for C24H31N4O7, 487.2187;
found 487.2181.
4.2.29. C5a-Piperazinylmethylminocycline (34)27. Anhydrous mag-
nesium bromide (51.0 mg, 0.276 mmol, 2.0 equiv) was added toa solution of the C5aeC11a-bridged cyclopropane 20 (105 mg,
0.138 mmol, 1 equiv) and tert-butyl 1-piperazine carboxylate
(186 mg, 1.00 mmol, 7.2 equiv) in tetrahydrofuran (2.0 mL) at
23 C. The reaction flask was sealed and the reaction mixture was
heated to 45 C. After stirring at 45 C for 36 h, the reaction
mixture was allowed to cool to 23 C. The cooled mixture was
partitioned between dichloromethane and saturated aqueous so-
dium bicarbonate solution (25 mL each). The phases were sepa-
rated and the aqueous phase was extracted with dichloromethane
(25 mL). The organic extracts were combined and the combined
solution was dried over anhydrous sodium sulfate. The dried so-
lution was filtered and the filtrate was concentrated. The product
mixture was filtered through a short pad of silica gel (eluting with
40% ethyl acetate/hexanes) and the filtrate was concentrated,
affording an orange-yellow oil. Methanol (2.5 mL) and dioxane
(2.5 mL) were added to the crude ring-opened product (33),
forming an orange-yellow solution. Palladium black (25 mg,
0.235 mmol, 1.7 equiv) was added in one portion at 23 C. An at-
mosphere of hydrogen was introduced by briefly evacuating the
flask, then flushing with pure hydrogen (1 atm). The reaction
mixture was stirred at 23 C for 2 h, then was filtered through
a plug of Celite. The filtrate was concentrated, providing an orange
solid. Concentrated aqueous hydrofluoric acid (48 wt %, 1.5 mL)
was added to a solution of the crude product in acetonitrile
(2.0 mL) in a polypropylene reaction vessel at 23 C. The reaction
mixture was stirred vigorously at 23 C for 14 h. Excess hydro-
fluoric acid was quenched by the careful addition of methoxy-
trimethylsilane (10.0 mL). The resulting mixture was
concentrated. The product was purified by preparative HPLC on an
Agilent Prep C18 column [10 mm, 25021.2 mm, UV detection at
350 nm, solvent A: 0.1% trifluoroacetic acid in water, solvent B:
acetonitrile, 2 batches, injection volume (for each batch): 5.0 mL
(4.0 mL 0.1% trifluoroacetic acid in water, 1.0 mL acetonitrile),
gradient elution with 5/35% B over 50 min, flow rate: 7.5 mL/
min]. Fractions eluting at 22e29 min were collected and concen-
trated, affording C5a-piperazinylmethylminocycline bistri-
fluoroacetate 34 as a yellow solid (63 mg, 58%, three steps). 1H
NMR (600 MHz, CD3OD, bistrifluoroacetate) d 7.58 (d, 1H,
J¼9.6 Hz), 6.93 (d, 1H, J¼9.0 Hz), 4.06 (s, 1H), 3.44 (d, 1H,
J¼16.2 Hz), 3.11 (br d, 1H, J¼12.6 Hz), 3.08e3.02 (m, 2H), 3.05 (s,
6H), 3.01e2.95 (m, 2H), 2.82 (s, 6H), 2.61e2.56 (m, 3H), 2.50 (d,
1H, J¼16.2 Hz), 2.48e2.42 (m, 3H), 2.20 (dd, 1H, J¼13.8, 3.0 Hz),
1.74 (dd, 1H, J¼14.1, 13.9 Hz); HRMSeESI (m/z): [MþH]þ calcd for
C28H38N5O7, 556.2766; found, 556.2771.
4.2.30. General procedure for final-step diversification of C5a-
aminomethylminocycline (32) and C5a-piperazinylmethylminocycline
(34). 4.2.30.1. C5a-N-acetylaminomethylminocycline (35). Acetyl
chloride (0.9 mL, 0.013 mmol, 2.3 equiv) was added to a solution of
C5a-aminomethylminocycline bistrifluoroacetate 32 (4.0 mg,
0.0056 mmol, 1 equiv) and N,N-diisopropylethylamine (4.6 mL,
0.027 mmol, 4.8 equiv) in methanol (200 mL) at 0 C. The resulting
solution was allowed to warm to 23 C over 5 min. The reaction
mixture was stirred at this temperature for 1 h, then was concen-
trated. The product was purified by preparative HPLC on an Agilent
Prep C18 column [10 mm, 25021.2 mm, UV detection at 350 nm,
solvent A: 0.1% trifluoroacetic acid in water, solvent B: acetonitrile,
injection volume: 5.0 mL (4.0 mL 0.1% trifluoroacetic acid in water,
1.0 mL acetonitrile), gradient elution with 5/40% B over 50 min,
flow rate: 7.5 mL/min]. Fractions eluting at 25e28 min were col-
lected and concentrated, affording C5a-N-acetylaminomethylmino-
cycline trifluoroacetate 35 as a yellow solid (3.2 mg, 89%). 1H NMR
(600 MHz, CD3OD, trifluoroacetate) d 7.80 (d, 1H, J¼9.0 Hz), 7.03 (d,
1H, J¼9.0 Hz), 3.89 (s, 1H), 3.46 (d, 1H, J¼14.4 Hz), 3.27 (d, 1H,
J¼13.8 Hz), 3.23 (d, 1H, J¼16.8 Hz), 3.15e3.08 (m, 13H), 2.63 (d, 1H,
J¼16.2 Hz), 2.11 (dd, 1H, J¼14.4, 2.4 Hz), 1.91 (s, 3H), 1.69 (dd, 1H,
P.M. Wright, A.G. Myers / Tetrahedron 67 (2011) 9853e9869 9869J¼13.9, 13.8 Hz); HRMSeESI (m/z): [MþH]þ calcd for C26H33N4O8,
529.2293; found 529.2299.
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